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ABSTRACT
Khaled Aryanfar
Tuberculosis (TB) progress toward Millennium Development Goals (MDGs) and
Directly Observed Therapy, Short-course (DOTS) in WHO Eastern Mediterranean
Region (EMR)
(Under direction of Frances McCarty, PhD )
Background: Tuberculosis (TB) is an airborne infection. Though effective anti-TB drugs
have been available for more than 50 years, over one-third of the world’s population is
exposed to TB bacterium; deaths due to TB infection occur at high frequency every day
worldwide. Today, drug-resistant TB, TB/HIV co-morbidity and poor health
infrastructure are major challenges worldwide, particularly in less developed countries.
Objectives: The primary objective of the study was to assess the progress of TB control
programs in twenty-two Eastern Mediterranean Region countries toward Millennium
Development Goals (MDGs) including implementation of the Directly Observed
Treatment, Short-course (DOTS). Also, the study was designed to explore TB/HIV comorbidity and to assess some factors potentially associated with TB progress in the
region.
Methods: Secondary data, obtained from the World Health Organization, World Bank,
and World Resource Institute on line databases were used. Paired samples t-test and
bivariate correlation were conducted.
Results: Between 1990 and 2005, TB incidence had decreased 9%, TB prevalence had
decreased 37% (statistically significant) and TB mortality had decreased 28%;
nevertheless, MDG targets were not met. TB/HIV co-morbidity increased in the region
especially in HIV-high burden countries. Though DOTS population coverage was
increased to 94% in 2005, DOTS new smear-positive case detection rate was 61% (target
70%) and DOTS treatment success was 80% (target 85%). Thus, the 1991 Stop TB
Partnership targets were not met.
Conclusions: In spite of the progress of TB control programs in the EMR, MDGs and
DOTs targets of 2005 were not obtained. Further efforts such as allocation of more
resources, strengthening of TB surveillance systems, extension of drug-resistant TB and
TB/HIV collaborative programs, and TB research are required to achieve MDGs by 2015
and to fully implement the new Stop TB Strategy in the region.
INDEX WORDS: TB burden, TB/HIV co-morbidity, and Eastern Mediterranean Region

CHAPTER I
INTRODUCTION
Tuberculosis (TB) is an airborne infectious disease that is preventable and
curable. Though effective drugs to treat and cure the disease have been available for more
than 50 years, over one-third of world’s population has been exposed to TB bacterium,
and new infections occur at a rate of one person per second, indeed, someone with TB is
dying every 15 seconds in the world. Left untreated, a person with active TB will infect
an average of 10 to 15 other people every year. Not everyone infected develops the full
blown disease; asymptomatic, latent TB infection is most common. However, one in ten
latent infections will progress to active TB, which, if left untreated, kills more than half
of its victims. In 2005, mortality and morbidity statistics included 14.6 million chronic
TB cases, 8.9 million new cases and 1.6 million deaths, mostly in developing countries. If
TB disease is detected early and fully treated, people with the disease quickly become
non-infectious and eventually cured. Multidrug-resistant TB (MDR-TB) and extensively
drug-resistant TB (XDR-TB), HIV-associated TB, and poor health infrastructure are
major challenges worldwide (1-6).
The goals of TB control programs are to reduce mortality, morbidity and
transmission of the disease, while preventing drug resistance, until it no longer poses a
threat to public health. TB control programs also aim to reduce human suffering and the
social and economic burden families and communities have to bear as a consequence of
the disease. The persistence of TB has been due chiefly to the neglect of TB control by
1

governments, poorly managed TB control programs, poverty, population growth and
migration, and a significant rise of TB cases in HIV endemic areas. To address the
situation, a global strategy called Directly Observed Therapy, Short-course (DOTS) was
introduced in 1991. DOTS has been implemented in joint TB/HIV programs with costeffective results and a treatment success rate of 72% (7-10). Furthermore, at the United
Nations Millennium Summit in 2000, world leaders agreed to set of time bound and
measurable goals and targets combating poverty, hunger, disease, illiteracy,
environmental degradation and discrimination against women, called Millennium
Development Goals (MDGs). One of them, specifically MDG 6, target 8 says, ―Halting
TB prevalence and death to half by 2015 and begin to reverse the incidence of TB.‖ (11).
The Global Plan to Stop TB 2006-2015, launched in 2006, was initiated to reduce
TB burden through contributions of both developing and developed countries. We can
achieve MDGs if the Global Plan to Stop TB is effectively implemented. Successful
implementation could tremendously decrease prevalence and death rate of TB, Multidrug resistant TB (MDR-TB), and TB/HIV co-infection (11).
TB is an important public health problem in the Eastern Mediterranean Region
(EMR). Every year the disease kills about 136,000 people and affects approximately
630,000 more. These numbers maybe fueled by political and economic instability,
migration and displacement, HIV/AIDS, poverty, malnutrition, poor health infrastructure,
and drug-resistant strains (12-17). The DOTS strategy was introduced in the Eastern
Mediterranean region in the mid-1990s. Most countries in the region have DOTS. In
2005, the regional DOTS coverage was close to 90% and the regional average treatment
2

success rate was about 84%.Though TB burden (incidence, prevalence and death rates)
decreased ―between 1980 to 2005‖, there are still many challenges to address in the
region. The regional case detection rate is expected to be only 45% by the end of 2005.
Case detection in the two high-burden countries of the region – Pakistan and Afghanistan
– is still quite low at 17% and 18%, respectively. Key components of DOTS, particularly
case-finding and surveillance are of low quality. Coverage of drug resistance TB and HIV
–TB co infection surveillance is low as well. In sum, much effort is needed to achieve
MDGs through implementation of the Global Plan to Stop TB and DOTS (12, 13, 15, 1720).
Study Objectives and Research Questions
The study objectives are to identify and describe the progress and barriers of TB
control programs in 22 EMR countries toward MDGs and 1991 National Health
Assembly (NHA) targets for DOTS. The study also explores TB prevention programs in
different countries based on different variables such as political stability, population
density, literacy, GDP, income, health service coverage, healthcare force, health
expenditure, HIV prevalence, immunization coverage, sanitation, and nutrition. The
specific questions are:


Has the Eastern Mediterranean region made progress towards achieving MDGs
and DOTS?



How is TB/HIV co-morbidity in the region?



Does the achievement of EMR countries differ in terms of infrastructure
variables?
3



What are some of the data gaps, challenges and accomplishments to be used as
lessons for future interventions?

Study significance
The present research is coincident with the endpoint of the 1991 NHA targets for
DOTS and the midpoint towards achieving MDGs in 2005. Therefore, this study
attempted to conduct an assessment of the TB situation and TB control programs in the
Eastern Mediterranean region. The findings of the study can be used by WHO, EMRO,
relevant ministries of public health and the public health community. Furthermore, this
study will provide some general and data-based recommendations on the feasibility of
adopting or enhancing existing TB control strategies for the region.

4

CHAPTER II
REVIEW OF THE LITERATURE
The literature review was written based on information from about 60 articles and
abstracts, and reports, figures and web pages (about 99 references) obtained via Pubmed,
Global, Google, WHO, StopTB, Wekimedia, CDC, and revolutionhealth websites.
Tuberculosis (TB) is a common and deadly infectious disease caused by
Mycobacterium, mainly Mycobacterium tuberculosis (MTB). Tuberculosis most
commonly attacks the lungs (Pulmonary TB), but can affect any parts of the body such as
the central nervous system, the lymphatic system, the circulatory system, the
genitourinary system, bones, joints and even the skin. Some types of Mycobacterium
such as Mycobacterium Bovis, Mycobacterium Africanum, Mycobacterium Canetti, and
Mycobacterium Microti can also cause tuberculosis, but these species do not usually
infect healthy adults. Though effective drugs to treat and cure the disease have been
available for more than 50 years, over one-third of world’s population has been exposed
to TB bacterium. New infections occur at a rate of one person per second, and someone
with TB is dying every 15 seconds in the world. Left untreated, a person with active TB
will infect an average of 10 to 15 other people every year. Not everyone infected
develops the full blown disease; asymptomatic, latent TB infection is most common.
However, one in ten latent infections will progress to active TB, which, if left untreated,
kills more than half of its victims. In 2004, mortality and morbidity statistics included
5

14.6 million chronic TB cases, 8.9 million new cases and 1.6 million deaths, mostly in
developing countries (1-6).
Tuberculosis has plagued human beings for millennia. Signs of tubercular damage
have been found in Egyptian mummies and in bones dating back at least 5,000 years (5,
6). Today, despite advances in treatment, TB is a global pandemic, fueled by the spread
of HIV/AIDS, poverty, poor health infrastructure and the emergence of drug-resistant
strains of the bacterium that causes the disease. ―Between 2000 to 2004‖, about 20% of
TB cases were resistant to standard treatment, and approximately 2% resistant to secondline drugs. The World Health Organization (WHO) declared TB a global health
emergency in 1993, and the Stop TB Partnership developed a Global Plan to stop TB,
aiming to save 14 million lives ―between 2006 and 2015‖(1-6).
MTB and TB transmission
Mycobacterium tuberculosis (MTB) is an aerobic bacterium that divides every 16
to 20 hours, an extremely slow rate compared with other bacteria, which usually divide in
less than an hour. For example, E.coli, one of the fastest-growing bacteria divides every
20 minutes. MTB is classified as a Gram-positive bacterium, since it has a cell wall but
lacks a phospholipid outer membrane. However, if a Gram stain is performed, MTB
either stains very weakly Gram-positive or does not retain dye due to the high lipid and
mycolic acid content of its cell wall. MTB is a small rod-like bacillus that can withstand
weak disinfectant and survive in a dry state for weeks. In nature, it can only grow within
the cells of a host organism, but MTB can be cultured in vitro. Scientists can identify
MTB under a regular microscope, using certain histological techniques on expectorate
6

samples from phlegm. MTB is classified as an acid-fast bacillus (AFB), since it retains
certain stains after being treated with acidic solution. Ziel-Neelsen stain is the most
common staining technique, which dyes AFBs a bright red that stands out clearly against
a blue background. Other ways to visualize AFBs include an auramine-rhodamine stain
and fluorescent microscopy (6).
When people with active pulmonary TB cough, sneeze, speak, kiss or spit, they
expel infectious aerosol droplets 0.5 to 5 µm in diameter. For instance, a single sneeze
can release up to 40,000 droplets. Since the infectious dose of TB is low, inhalation of
only a single bacterium can cause a new TB infection. People with prolonged, frequent,
or intense contact are at particularly high risk of becoming infected, with an estimated
22% infection rate. A person with active but untreated TB can infect 10-15 other people
per year. Others at risk include people who live in TB endemic areas, residents and
employees of high risk congregate settings, medically underserved and low income
population, children exposed to adults in high risk categories, and immunocompromised
people. In sum, transmission can only occur from people with active—not latent—TB.
The probability of transmission from one person to another depends upon the number of
infectious droplets expelled by a carrier, the effectiveness of ventilation, the duration of
exposure, and the virulence of the M. tuberculosis strain, so the chain of transmission can
therefore be broken by isolating patients with active disease and starting effective anti-TB
therapy. After two weeks of such treatment, people with non-resistant active TB
generally cease to be contagious. Rarely, a pregnant woman with an active TB disease
may pass the bacteria to her fetus (1-6).

7

Pathogenesis
It is estimated about 90% of infected people with MTB have asymptomatic,
latent TB infection (LTBI), and only 10% of LTBI will progress to active TB. However,
if untreated, the death rate for these active TB cases is more than 50%. TB infection
begins when the mycobacterium reaches the pulmonary alveoli, where they invade and
replicate within alveolar macrophages. The primary site of infection in the lungs is called
the Ghon focus. Bacteria are picked up by dendrite cells, which do not allow replication,
although these cells can transport the bacilli to local (mediastinal) lymph nodes. MTB
further spreads through the bloodstream to the more distant tissues and organs, where
secondary TB lesions can develop in lung apices, peripheral lymph nodes, kidneys, brain,
and bones. All parts of the body can be affected by the disease, though it rarely affects
the heart, skeletal muscles, pancreas and thyroid. Tuberculosis is classified as one of the
granulomatous inflammatory conditions. Macrophages, T lymphocytes, B lymphocytes
and fibroblasts are among the cells that aggregate to form a granuloma, with lymphocytes
surrounding the infected macrophages. The granuloma functions not only to prevent
dissemination of the mycobacterium, but also provides a local environment for
communication of cells of the immune system. Within the granuloma, T lymphocytes
(CD4+) secrete cytokines such as interferon gamma, which activates macrophages to
destroy the bacteria with which they are infected. T lymphocytes (CD8+) can also
directly kill infected cells. Importantly, bacteria are not always eliminated within the
granuloma, but can become dormant, resulting in a latent infection.

8

Another feature of the granulomas of human tuberculosis is the development of
cell death, or necrosis, in the center of tubercles. To the naked eye this has the texture of
soft white cheese and was termed caseous necrosis. If TB bacteria gain entry to the
bloodstream from an area of damaged tissue they spread through the body and set up
many foci of infection, all appearing as tiny white tubercles in the tissues. This severe
form of TB disease is most common in infants and the elderly and is called miliary
(disseminated) tuberculosis. Patients with disseminated TB have a fatality rate of
approximately 20%, even with intensive treatment. Tissue destruction and necrosis are
balanced by healing and fibrosis. Affected tissue is replaced by scarring and cavities
filled with cheese-like white necrotic material. During active disease, some of these
cavities are joined to the air passages, or bronchi and this material can be coughed up.
The material contains living bacteria and can therefore pass on infection. Treatment with
appropriate antibiotics kills bacteria and allows healing to take place. Upon cure, affected
areas are eventually replaced by scar tissue (5, 6).
Clinical features
As mentioned previously, TB spreads through airborne droplets when a person
with the infection coughs, talks, sings or sneezes. In general, a person needs prolonged
exposure to an active TB patient before becoming infected by TB. Even then, symptoms
of the disease may not develop, or may develop many years later. Doctors make a
distinction between LTBI and active TB:

Latent TB Infection (LTBI): In most people who breathe in TB bacteria and become
infected, the body is able to fight the bacteria to stop them from growing. The bacteria
9

become inactive, but they remain alive in the body and can become active later. People
with LTBI have no symptoms, are not contagious, and usually have a positive skin test
reaction or QuantiFERON-TB Gold test (QFT-G). They may develop active TB disease
if they do not receive treatment for LTBI (1, 2, 5, and 6).

Active TB: TB bacteria become active if the immune system cannot stop them from
growing. The active bacteria begin to multiply in the body and cause active TB disease.
The bacteria attack the body and destroy tissue. If this occurs in the lungs, the bacteria
can actually create a hole in the lung. Some people develop active TB disease soon after
becoming infected, before their immune system can fight the TB bacteria. Other people
may get sick later, when their immune system becomes weak for another reason. Babies,
young children, people infected with HIV, people with conditions such as substance
abuse, diabetes mellitus, silicosis, cancer, Leukemia, Hodgkin’s disease, severe kidney
disease, low body weight, etc can develop the disease rapidly. Symptoms of TB depend
on where in the body the TB bacteria are growing. TB bacteria usually grow in the lungs.
TB in the lungs may cause symptoms such as a cough lasting three or more weeks that
may produce discolored or bloody sputum, unintended weight loss, fatigue, slight fever,
night sweats, chills, loss of appetite, and pain with breathing or coughing (pleurisy) (1, 2,
5, 6).

Tuberculosis also can target almost any part of the body, including joints, bones,
urinary tract, central nervous system, muscles, bone marrow and lymphatic system. When
TB occurs outside the lungs, signs and symptoms vary, depending on the organs
involved. For example, tuberculosis of the spine may result in back pain, and tuberculosis
10

that affects the kidneys might cause blood in urine. Tuberculosis can also spread through
the entire body, simultaneously attacking many organ systems. Left untreated TB can
cause some life- threatening complications and death (1, 2, 5, and 6).

Pulmonary TB can cause permanent lung damage when it is not diagnosed and
treated early. Untreated active disease can also spread to other parts of the body where it
can lead to serious or life-threatening complications. TB that infects the bone, for
example, can cause severe pain, abscesses and joint destruction (5).

Meningeal TB, which occurs when TB infects the brain and central nervous
system, and miliary TB, which occurs when TB bacteria spread throughout the entire
body, are particularly dangerous forms of the disease. Children are especially susceptible
to both meningeal TB and miliary TB (5). Recurrent TB is the most serious complication,
which occurs after the initial infection and the development of drug-resistant strains of
the disease (5)

Diagnosis

TB can be a difficult disease to diagnose, due mainly to the difficulty in culturing
of this slow-growing organism in the laboratory. A complete medical evaluation for TB
must include a medical history, a chest X-ray, and a physical examination. It may also
include tuberculin skin test, serological test, microbiological smears and cultures (5, 6).

Tuberculin test: The most commonly used diagnostic tool for TB is a simple skin test.
Although there are two methods, doctors consider the Mantoux test the more accurate.
11

The Mantoux skin test consists of an intradermal injection of exactly one tenth of a
milliliter (mL) of purified protein derivatives (PPD) of MTB tuberculin in the forearm.
Within 48 to 72 hours, a health care professional will check the arm for a local reaction to
the injected material. Depending on the response, the test is diagnosed as positive usually shown by a hard, raised bump at the injection site (5-15 mm). This means the
person is likely to have TB infection. The Mantoux test is not perfect – it is possible to
have either a false-positive or false-negative test. A false-positive test occurs when a
person is infected with a mycobacterium other than the one that causes TB, or if a person
has ever been vaccinated with Bacillus Calmette-Guerin (BCG), a TB vaccine which is
widely used in countries with high TB infection rates. False negative results occur in
conditions such as severely weakened immune system, vaccinations with live viruses
such as Measles and Small pox, improper testing, overwhelming TB disease, and recent
TB infection which takes eight to ten weeks for the body to react after infection (5, 6).

Recent TB tests: As a replacement for the Mantoux test, several other tests are being
developed. QuantiFERON-TB Gold (QFT) is a blood test that measures the patient’s
immune reactivity to the TB bacteria and is useful for initial and serial testing of persons
with an increased risk of latent or active tuberculosis infection. Results of this test may
be available in as soon as one day. Guidelines for the use of QuantiFERON-TB Gold
were released by the CDC in December 2005. However, the test is not yet widely
available. Researchers in October 2006 also reported encouraging results from another
test under investigation for use primarily in developing countries. It's called the
microscopic-observation drug-susceptibility (MODS) assay and relies on sputum samples
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to detect the presence of TB bacteria. MODS produces accurate results in as little as
seven days. Additionally, the test can identify drug-resistant strains of the TB bacteria. If
the results of a TB test are positive, then further tests can be conducted to help determine
whether you have active TB disease (5, 6).

Chest X-ray: When a person has a positive skin test, the doctor is likely to order a chest
X-ray. In some cases, this may show white spots where the immune system has walled
off TB bacteria. In others, it may reveal a nodule or cavities in the lungs caused by active
TB (5).

Culture tests: If a chest X-ray shows signs of TB or a urine sample indicates infection, the
doctor may take a sample of stomach secretions or sputum - the mucus that comes up
when the person coughs. The samples are tested for TB bacteria, and the doctor can have
the results of special smears in a matter of hours. Although it takes longer, samples may
also be sent to a laboratory where they are examined under a microscope as well as
placed on a special medium that encourages the growth of bacteria (culture). The bacteria
that appear are then tested to see if they respond to the medications commonly used to
treat TB. The doctor uses the results of the culture tests to prescribe the most effective
medications for the patient (5).
TB diagnosis in children: It is harder to diagnose TB in children than in adults – they are
far less likely than adults to have signs and symptoms of the disease, even when they are
quite sick. Children also may swallow sputum, rather than coughing it out, making it
harder to take culture samples. Infants and young children may have no reactions to the
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skin test. For these reasons, presence of an adult who tests positive may be used to help
diagnose TB in a child (5).

TB Diagnosis in people with HIV/AIDS: Diagnosing TB in HIV-positive people can be
challenging, in part because signs and symptoms of HIV/AIDS are often similar to those
of TB. What is more, people with HIV may not react to a standard TB skin test, and Xrays, sputum tests and other exams may fail to show evidence of early TB infection (5).

Treatment

Until the mid-20th century, people with tuberculosis were routinely cared for in
sanitariums - often for years - where the clear, cold air, abundant food and enforced rest
were believed to heal the lungs and halt the wasting, characteristic of the disease. Often,
the treatment not only helped cure TB, but also prevented its spread. Today, medications
are the cornerstone of tuberculosis treatment. However, the therapy is lengthy. Normally,
a TB patient takes antibiotics for six to 12 months to completely destroy the bacteria. The
exact drugs and length of treatment depends on the age, overall health, the results of
susceptibility tests, and whether the parson has latent or active TB (5).

LTBI treatment: After confirming LTBI by TB tests, chemotherapy or preventive drug
therapy is recommended to destroy dormant bacteria that might become active in the
future. The standard treatment is a daily dose of isoniazid (INH) for six to nine months.
Long-term use can cause side effects, including the life-threatening liver disease,
hepatitis. Also taking medication such as acetaminophen, aspirin, and alcohol greatly
increase risk of liver damage during treatment (5, 6).
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Active TB treatment: The standard "short" course treatment for active TB is isoniazid,
rifampicin, pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin
alone for additional four months. The patient is considered cured at six months (although
there is still a relapse rate of 2 to 3%). If the organism is known to be fully sensitive, then
treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by
isoniazid and rifampicin for four months. Ethambutol needs to be not used 1, 2. There are
six classes of second-line drugs (SLDs) used for the treatment of TB. A drug is classified
as second-line instead of first-line for one of the following reasons: it may be less
effective than the first-line drugs (e.g., p-aminosalicylic acid), it may have toxic sideeffects (e.g., cycloserine), or it may be unavailable in many developing countries (e.g.,
fluoroquinolones). The six classes of SLDs are as follows:


aminoglycosides: e.g., amikacin (AK), kanamycin



polypeptides: e.g., capreomycin, viomycin, enviomycin



fluoroquinolones: e.g., ciprofloxacin (CIP), moxifloxacin (MXF)

1

Standard abbreviations: All first-line anti-TB drug names have a standard three-letter and a single-letter
abbreviation: such as streptomycin is STM or S, isoniazid is INH or H, rifampicin is RMP or R, ethambutol
is EMB or E, pyrazinamide is PZA or Z. The US commonly uses abbreviations and names that are not
internationally recognized: rifampicin is called rifampin and abbreviated RIF; streptomycin is commonly
abbreviated SM (6).
2

Drug regimens: A prefix denotes the number of months the treatment should be given for; a subscript
denotes intermittent dosing (so 3 means three times a week) and no subscript means daily dosing. Most
regimens have an initial high-intensity phase, followed by a continuation phase (also called a consolidation
phase or eradication phase); the high-intensity phase is given first, then the continuation phase, the two
phases divided by a slash. So, 2HREZ/4 HR3 means isoniazid, rifampicin, ethambutol, pyranzinamide
daily for two months, followed by four months of isoniazid and rifampicin given three times a week (6).
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thioamides: e.g. ethionamide, prothionamide



cycloserine (the only antibiotic in its class)



p-aminosalicylic acid (PAS or P).

Other drugs that may be useful, but are not on the WHO list of SLDs: rifabutin;
macrolides: e.g., clarithromycin (CLR); linezolid (LZD); thioacetazone (T); thioridazine;
arginine; vitamin D; R207910. These drugs may be considered "third-line drugs" and are
listed here either because they are seldom effective (e.g., clarithromycin) or because their
efficacy has not been proven (e.g., linezolid, R207910). Rifabutin is effective, but is not
included on the WHO list as in most developing countries, it is impractically expensive
(5, 6).
TB is treated with combination therapy 2HREZ/4HR3 2 (except LTBI or
chemoprophylaxis), because regimens that use only single drugs result in the rapid
development of resistance and treatment failure. The rationale for using multiple drugs to
treat TB is based on simple probability. A patient with extensive pulmonary TB has
approximately 1012 bacteria in his/her body, and therefore will probably be harboring
approximately 105 EMB-resistant bacteria, 104 STM-resistant bacteria, 104 INH-resistant
bacteria and 10² RMP-resistant bacteria. Resistance mutations appear spontaneously and
independently, so the chances of the patient harboring a bacterium that is spontaneously
resistant to both INH and RMP is 1 in 10 6, and the chances of the patient harboring a
bacterium that is spontaneously resistant to all four drugs is 1 in 10 11. There are other
theoretical reasons for supporting combination therapy. The different drugs in the
regimen have different modes of action: INH and EMB are bacteriostatic (they stop the
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bacteria replicating, but do not kill them); RMP is bactericidal (it actually kills bacteria)
(6).

Completing treatment is essential because TB bacteria grow slowly; treatment for
an active infection is lengthy - usually six to 12 months. After a few weeks, the patient
may not be contagious and may start to feel better, but it is essential that he/she finishes
the full course of therapy and takes the medications exactly as prescribed by the doctor.
Stopping treatment too soon or skipping doses can create drug-resistant strains of the
disease that are more dangerous and difficult to treat. Drug-resistant strains that are not
treated can quickly become fatal, especially in people with impaired immune systems. In
an effort to help people stick with their treatment regimen, some doctors and clinics use a
program called directly observed therapy (DOT). In this approach, a nurse or other health
care professional administers the medication so that the TB patient does not have to
remember to take it on his/her own (5).

Treatment side effects of TB drugs are not common, but can be serious when they
do occur. TB medications can be highly toxic to the liver. When taking these
medications, side effects such as nausea, vomiting, loss of appetite, jaundice, fever,
abdominal tenderness or soreness, and blurred vision or colorblindness will generally
appear (5).

Drug-resistant TB treatment: Multidrug-resistant TB (MDR-TB) is any strain of TB that
cannot be treated by the two most powerful TB drugs, isoniazid and rifampin. Extensive
drug-resistant TB (XDR-TB) is a newly developed strain of TB that is resistant to the
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same treatments that MDR-TB is, and additionally XDR-TB is resistant to three or more
of the second-line TB drugs. Both strains develop as a result of partial or incomplete
treatment - either people skip doses, or do not finish their entire course of medication, or
because they are given the wrong treatment regimen. This gives bacteria time to undergo
mutations that can resist treatment with first-line TB drugs. MDR-TB can be treated, but
it requires at least two years of therapy with second-line medications that can be highly
toxic. Even with treatment, many people with MDR-TB may not survive. And even when
treatment is successful, people with this form of TB may need surgery to remove areas of
persistent infection or repair lung damage. Treating these resistant forms of TB is far
more costly than treating nonresistant TB, making therapy unaffordable in many parts of
the world. Because these resistant infections are spreading and could potentially make all
TB incurable, some experts believe that ineffective treatment is ultimately worse than no
treatment at all (5).

HIV/AIDS co-infected TB patient treatment: Treating TB people who are co-infected
with HIV/AIDs is a particular challenge. HIV-positive people are especially likely to
develop MDR-TB and to rapidly progress from latent to active infection. What is more,
the most powerful AIDS drugs - protease inhibitors - interact with rifampin and other
drugs used to treat TB, reducing the effectiveness of both types of medications. To avoid
interactions, people living with both HIV and TB may stop taking protease inhibitors
while they complete a short course of TB therapy that includes rifampin. Otherwise, they
may be treated with a TB regimen in which rifampin is replaced with another drug that is
less likely to interfere with HIV/AIDS medications. In such cases, doctors carefully
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monitor the response to therapy, and the duration and type of regimen may change over
time. Without treatment, most people living with both HIV and TB will die, often in a
matter of months. In such cases, the primary cause of death is TB, not HIV/AIDS (5).

Prevention

There are two parallel approaches to prevent and control TB. First, people with
TB and their contacts should be identified and then treated (secondary or tertiary
prevention). Identification of infections often involves testing high-risk groups for TB.
Second, children should be vaccinated to protect them from TB (primary prevention).
Unfortunately, no vaccine is available to provide reliable protection for adults. However,
in tropical areas where the incidence of atypical mycobacterium is high, exposure to nonTB mycobacterium gives some protection against TB (5, 6).

Experts also advise an annual skin test for people who have HIV or any other
immunocompromised disease, live or work in a prison or nursing home, health facilities,
or have a substantially increased risk of exposure to the disease (5). If the test was
positive for latent TB, chemotherapy with isoniazid can reduce the risk of developing
active TB in the future (5).

Bacille Calmette-Guérin (BCG) is a vaccine against TB that is prepared from a
strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium
bovis, that has lost its virulence3 in humans by being specially cultured in an artificial
3

Virulence: The disease-producing power of a microorganism; infectiousness 6. Wikimedia. Tuberculosis.
http://en.wikipedia.org/wiki/Tuberculosis..
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medium for years. The bacilli have retained enough strong antigenicity to become a
somewhat effective vaccine for the prevention of human TB. Many countries with high
prevalence of TB use BCG vaccine as part of their TB control programs, especially for
infants. This was the first vaccine for TB, developed at the Pasteur Institute in France
―between 1905 and 1921‖. However, mass vaccination with BCG did not start until after
World War II. The protective efficacy of BCG for preventing serious forms of TB (e.g.
meningitis) in children is greater than 80%; its protective efficacy for preventing
pulmonary TB in adolescents and adults is variable, ranging from 0 to 80%. However, as
previously stated, vaccination with BCG also causes a false-positive result on a Mantoux
skin test . Therefore, it is not recommended for general use in the United States.
Researchers are working on developing more effective TB vaccines (5, 6).

Adherence to medication is the most important step to protect the patient and
others from of TB. As previously described, when the patient stops treatment early or
skip doses, TB bacteria have a chance to develop mutations resistant to the most potent
TB drugs. The resulting drug-resistant strains are much more deadly, expensive and
difficult to treat (5).

Quarantine of the patient can be beneficial. Keeping the patient isolated, covering
the mouth of the patient during the first 2-3weeks, and safe disposal of materials
contaminated with the patient sputum may lessen the risk of transmission (5).
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Public health significance:
TB Epidemiology
TB is still a major cause of death worldwide, but data has shown that the global
epidemic is on the threshold of decline. According to the World Health Organization
(WHO), nearly two billion people—one–third of the world's population—have been
exposed to the tuberculosis pathogen.
Annually, about eight million people become ill with TB, and two million people
die from the disease, worldwide. In 2005, around 14.6 million people had active TB
disease with nine million new cases, 7.4 million of them in Asia and sub-Saharan Africa.
A total of 1.6 million people died of TB, including 195 000 patients infected with HIV.
Between 1980 and 2005, 90 million TB patients were registered in national surveillance
systems and reported to WHO, also more than 26 million were notified by DOTS
programs since 1995. This vast body of surveillance data suggested the global TB
incidence rate peaked sometime between 2000-2005, although the total number of new
cases is still rising each year. Data shows the global TB epidemic is now on the threshold
of decline (21).TB prevalence and death rates have probably been falling globally for
several years. In 2005, the TB incidence rate was stable or in decline in across WHO
regions4, and had reached a peak worldwide. However, the total number of new TB cases
was still rising slowly, because the case-load continued to grow in the African, Eastern
Mediterranean and South-East Asia regions. The estimated annual incidence rate varies
from 356 per 100,000 in Africa to 41 per 100,000 in the Americas (5, 6, and 21).
4

WHO six regions are; African region (AFR), the Region of Americas (AMR), the Eastern Mediterranean
Region (EMR), the European Region (EUR), the South East Asia region (SEAR), and the Western Pacific
Region (WPR) (3).
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Tuberculosis is the world's greatest infectious killer of women of reproductive age
and the leading cause of death among people with HIV/AIDS. In 2004, the country with
the highest repeated incidence of TB was South Africa, with 718 cases per 100,000
people. India has the largest number of infections, with over 1.8 million cases. In
developed countries, tuberculosis is less common and is mainly an urban disease. In the
United Kingdom, TB incidences range from 40 per 100,000 in London to less than 5 per
100,000 in the rural South West of England; the national average is 13 per 100,000.In the
United States, the overall tuberculosis case rate was 4.9 per 100,000 persons in 2004.The
incidence of TB also varies with age. In Africa, TB primarily affects adolescents and
young adults. However, in countries where TB has gone from high to low incidence, such
as the United States, TB is mainly a disease of older people (5, 6, and 21).
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Figure 1. Tuberculosis notification rates, 2005 (22)
Twenty -two countries have been recognized as high burden countries, which
account for approximately 80% of the estimated number of new TB cases (all forms)
arising worldwide each year. These 22 countries are not necessarily those with the
highest incidence rates per capita; many of the latter are medium-sized African countries
with a high rate of TB/HIV co-infection and they are under focus of intensified efforts of
DOTS expansion (21). Further information can be found in Figures 14, 21-26 in the
appendixes.
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TB Risk Factors
A number of factors have contributed to the global TB crisis, but the leading
cause is the spread of HIV, the virus that causes AIDS. Tuberculosis and HIV have a
deadly relationship - each fuels the progress of the other. Infection with HIV suppresses
the immune system, making it difficult for the body to control TB bacteria. As a result,
people with HIV are many times more likely to progress from dormant to active disease
than are people who are not HIV-positive. TB is one of the leading causes of death
among people living with AIDS - not only because they are more susceptible to TB, but
also because TB can increase the rate at which the AIDS virus replicates. One of the first
indications of HIV infection may be the sudden onset of TB - often in a site outside the
lungs (extra-pulmonary TB) (5).
Anyone of any age, race or nationality can contract TB, but certain factors
increase the risk of the disease (5).Weak immunity can increase the individual risk of
catching TB. When the immune system is healthy, macrophages can often successfully
wall off TB bacteria, but the body cannot mount an effective defense if the resistance is
low. A number of factors can weaken the immune system such as HIV/AIDS, diabetes,
the lung disease silicosis, receiving treatment with corticosteroids, arthritis medications,
substance abuse and long-term drug or alcohol use (23-26).
TB can occur at any point in the course of progression of an HIV infection. The
risk of developing TB rises sharply with worsening immune status.HIV promotes the
rapid progression of LTBI to active disease and is the most powerful known risk factor
for the activation of LTBI. Compared with an individual who is not infected with HIV, a
person infected with HIV has a 10 times increased risk of developing TB. TB is among
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the leading killers of people with HIV, and up to 50% of people with HIV or AIDS
develop TB. In some regions of Africa, up to 77% of TB patients also have HIV.
Worldwide, more than 21 million people are co-infected with TB and HIV, and 70% are
concentrated in Africa. A large number of these people will develop active TB if they do
not receive treatment. Co-infection is even starting influence the gender distribution of
TB in many African countries; as HIV prevalence among young African women rises,
they are also increasingly bearing the burden of TB (27-30).
By the end of 2000, about 11.5 million HIV-infected people worldwide were coinfected with M. tuberculosis. Seventy percent of co-infected people were in sub-Saharan
Africa, 20% in South-East Asia, 1% in Eastern Mediterranean, 1% in Europe, 4% in
Western Pacific and 4% in Latin America and the Caribbean approximately (31). Further
information is included in Figure 21 in the appendix.

TB is also associated with poverty. The majority of the poor in the world are
likely to have TB as result of contributing factors such as lack of basic health services,
poor nutrition and inadequate living conditions. In turn, illness and death from TB
reinforces and deepens poverty in many communities. For example, studies in India have
shown that the prevalence of TB is between two and four times higher among groups
with low income and no schooling. Overcrowded conditions, poor nutrition and
inadequate sanitation increase the probability of being infected and developing active TB.
Once they are ill, those who have limited access to health services are less likely to be
diagnosed and treated for TB. The greater the numbers of people with active TB in a
community, the more likely others are to become infected. This becomes a vicious circle
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in poor communities where TB flourishes. Therefore, it is no surprise at present; over
90% of TB cases and 90% of deaths from TB occur in developing countries. A key
challenge for TB control today is finding those people who have limited access to
effective TB treatment and curing them. Expanding innovative approaches such as
linking the public and private sectors in the treatment and referral of such cases will be
critical in reducing TB deaths among the poor. The problem is compounded because
people living in poverty and in unstable political situations often move or migrate and
therefore may not complete their treatment, leading to drug-resistant forms of the disease
(32-41).

Crowded living conditions also contribute to the spread of TB. TB spreads most
easily in cramped, crowded, poorly ventilated spaces. Incidence rates in prisons, juvenile
detention centers and homeless shelters are higher than that in the general population. TB
bacteria also can flourish in nursing homes because older adults often have immune
systems weakened by illness or aging (42-47).

Strains of TB that are resistant to conventional drugs have been documented in
every country. Drug-resistant TB is caused by inconsistent, impartial or inappropriate
treatment. People infected with drug-resistant TB, are highly contagious and transmit the
drug-resistant strain of TB to others. As a result, it is on the increase in developing and
transitional countries. Hotspots for multi-drug resistant TB are Estonia, Latvia and certain
regions in Russia and China. It is estimated that drug-resistant TB accounted for 3.2% of
the world’s new cases in 2000. Multi-drug resistant TB is more expensive and difficult to
treat. Before recent negotiations with pharmaceutical companies, it was over one hundred
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times more expensive to treat than conventional TB, with long-term treatment up to two
years with second line anti TB drugs which are highly toxic (48-60). Further information
is included in Figures 23-24 in the appendixes.

Malnutrition or poor diet and food low in calories, puts a person at greater risk of
TB and it may impair survival in TB patients. It is thought that chronic lack of appetite
can be one of the causes of malnutrition associated with TB and therefore maybe a
potential independent risk factor for latent TB. Latent TB infected people with poor
appetite develop active TB rapidly, and then these patients have poor treatment outcome.
Studies have shown that supplementation with a multivitamin, including Zn, during
treatment of pulmonary TB may reduce mortality in those co-infected with
HIV.Furthermore, malnutrition and intestinal parasites cause immunosuppression, which
in turn may cause false-negative tuberculin skin tests (TST) and failure to identify TB
infection (61-72).

Although more men than women are diagnosed with TB and die from it in most
of the world, TB is nevertheless a leading infectious cause of death among women.
Annually, about three-quarters of a million women die of TB, and over three million
contact the disease, accounting for about 17 million Disability Adjusted Life Years
(DALY). TB is a leading cause of death among women of reproductive age and is
estimated to cause more deaths among this group than all causes of maternal mortality.
As tuberculosis affects women mainly in their economically and reproductively active
years, the impact of the disease is also strongly felt by their children and families.
Mortality, incidence, and DALY indicators do not reflect this hidden burden of social
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impact. One of the reasons is women are less likely than men to be tested and treated for
TB. In addition, as greater numbers of women become infected with HIV, more are also
becoming sick with TB (73, 74). However, studies in AFG, a country with one of the
highest mortality rates (about 1600 per 100.000 population), have found about 66% of
TB detected cases were women. This maybe due to low access to basic health services,
poverty, malnutrition, and low access to sanitation (99).

Over 250 000 children die every year of TB. Children are particularly vulnerable
to TB infection because of frequent household contact. Children also suffer when their
parents are infected. Every year in India alone, more than 300 000 children leave school
on account of their parental TB (73, 74).Cases of TB in children usually represent
between 10% and 20% of all TB cases. The frequency of childhood TB in a given
population depends on the number of infectious cases, the closeness of contact with an
infectious case, the age of children when exposed to TB, and the age structure of the
population. Children rarely have sputum smear-positive TB and so it is unlikely they are
a powerful source of transmission. TB in children is mainly due to failure of TB control
in adults, the failure to cure infectious cases (patients with sputum smear-positive PTB).
Good treatment of TB in childhood will result in the following: a) improved well-being
through decreased morbidity and mortality; b) improved credibility and reputation of the
NTP; and c) less chance for children to have TB reactivation with cavitation 5 in later life
(31).

5

Cavitation: The formation of cavities in a body tissue or an organ, especially those formed in the lung as a
result of tuberculosis.
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Political stability is a term used to describe the socio-political climate or condition
of a country. It means absence of violence, absence of civil unrest, absence of guerrilla
warfare, governmental longevity, and the absence of structural change, legitimacy, and
effective decision making. Political and economic stability are important in implementing
public health programs and achieving its goals, particularly TB control programs.
Political and economic instability exacerbate other factors such as poverty, hunger,
immigration, displacement, malnutrition, and HIV/AIDS prevalence, which each fuels
TB epidemics. Sub-Saharan Africa and some other instable countries with high burden of
HIV-TB co-infection are good examples of instable countries (14, 75-83).

The association between smoking and TB has been investigated for several
decades. Both passive and active exposure to tobacco smoke has shown to be associated
with TB infection and with the transition from being infected to developing active TB
disease. There may be several reasons for the association between smoking and TB.
Smoking may decrease immune response or damage the protective effect of tiny hair-like
structures called cilia in the airways, resulting in increased TB risk. It has been shown
that ever smokers are more likely to have cough, dyspnea, chest radiograph appearances
of upper zone involvement, cavity and miliary appearance, and positive sputum culture,
but are less likely to have isolated extra-pulmonary involvement than non-smokers.
Smoking has been found to be associated with both relapse of TB and TB mortality.
There appears to be enough evidence to conclude that smoking is causally associated
with TB disease. Patients with TB need and should receive counseling and assistance in
stopping smoking. A meta-analysis study reported smokers, compared to nonsmokers,
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were 73 percent more likely to become infected with TB and more than twice as likely to
develop active TB. Overall, smokers are 40 to 60 percent more likely than nonsmokers to
develop active TB after being infected with TB bacteria (84-90).

Global TB Control Programs
The goals of TB control programs are to reduce mortality, morbidity and
transmission of the disease, while preventing drug resistance, until it no longer poses a
threat to public health. The programs also aim to reduce human suffering, including the
social and economic burden families and communities have to bear as a consequence.
The forty-fourth World Health Assembly (1991) set the targets for global TB control to
be achieved by the year 2000. The target was to cure 85% of the identified TB cases and
to detect overall 70% of such cases. In view of the slow progress in many high burden
countries, the target date was revised to 2005. Enabling achievement of high cure rates
for all, and especially infectious TB cases, remains the highest priority. Besides helping
to rapidly reduce transmission, TB programs achieving high cure rates are likely to attract
the great majority of existing cases. Giving priority to case finding before ensuring access
to high quality care for diagnosed cases could compound the TB problem by producing
chronic cases and MDR-TB. Improved and expanded case detection activities should
follow sustained achievement of high cure rates (8).
Countries are expected to achieve the global targets by integration of TB activities
into general health services, introduction of guidelines for health care providers on proper
management of respiratory diseases, incorporation of community health workers and
volunteers for service delivery, involvement of private and other non-governmental
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health providers and adaptation of DOTS implementation to suit local settings and
situations. This should result in reduction of TB morbidity, mortality and disease
transmission leading to a gradual decline in the epidemiological burden of the disease (8).
Directly Observed Therapy, Short-course (DOTS)
The forty-fourth World Health Assembly (1991) recognized the growing
importance of TB as a public health problem and the potential for cost-effective control
using currently available tools. This led to a reassessment of ongoing TB control efforts.
The persistence of TB has been due chiefly to the neglect of TB control by governments,
poorly managed TB control programs, poverty, population growth and migration, and a
significant rise of TB cases in HIV endemic areas. To help address the situation, a new
framework for effective TB control was then developed and a global strategy called
DOTS was introduced. DOTS – the internationally approved TB control strategy – has
been implemented together with TB/HIV programs, which has had cost-effective results
and high treatment success rate .DOTS is also an excellent model for delivering
antiretroviral (ARV) therapy to HIV infected people. Because nearly three-fourths of TB
patients are co-infected with HIV in high-burden countries, TB services form important
entry points for scaling up access to ARVs (7-10).
The five elements of the DOTS strategy, considered essential for global TB
control are (7-10):
a)

Political commitment with increased and sustained financing. Clear and sustained

political commitment by national government is crucial to ensure sustained,
comprehensive tuberculosis control activities. This political commitment helps to
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implement DOTS and the Stop TB Strategy effectively and to foster national and
international partnerships, which should be linked to long-term strategic action plans
prepared by NTPs. Strategic action plans should address technical and financial
requirements and promote accountability for results at all levels of the health system;
they should include TB-related and other relevant indicators, and – where appropriate –
political commitment should be backed up by national legislation. Local partnerships
with many potential contributors will help improve TB care in terms of access, equity and
quality. As current resources are inadequate, so further effort is required to mobilize
additional resources from domestic as well as international sources, with a progressive
increase in domestic funding. The global financing and partnership resources now
available for poverty reduction, health systems improvement and disease control offer
new opportunities for TB control programs. Even with adequate financing, critical
deficiencies in human resources in the health sector will impede progress in many lowand middle-income countries, especially in Africa. Therefore, Political commitment is
required to support the overall structural and financial changes needed to improve the
availability, distribution and motivation of competent health workers. Special efforts,
including good strategic planning, will be needed to ensure the availability of adequate
and competent human resources for health care in general and TB care in particular (710).
b)

Case detection through quality-assured bacteriology. Bacteriology remains the

recommended method of TB case detection, first using sputum smear microscopy and
then culture and drug susceptibility testing (DST) (80). A wide network of properly
equipped laboratories with trained personnel is necessary to ensure access to quality32

assured sputum smear microscopy. This is likely to require additional investments in the
laboratory network in many countries. In addition, every country should have a wellresourced and fully functioning national reference laboratory. The laboratory network
should be based on some principles such as; adoption based on international standards,
decentralization of diagnostic services, and communication at various level of network
and quality management. Culture and DST (80) services should be introduced in a phased
manner, at appropriate referral levels of the health system. Their functions should include
diagnosis of sputum smear-negative TB, diagnosis of TB among HIV-positive adults and
children, diagnosis and monitoring of response to treatment of MDR-TB, and testing
related to periodic surveys of the prevalence of drug resistance. Maintaining the quality
of the laboratory network depends on regular training, supervision and support, and
motivation of laboratory staff. Existing public and private laboratories should be used
wisely (7-10).
c)

Standardized treatment, with supervision and patient support. Standardized short-

course chemotherapy, using regimens of six to eight months are recommended, for at
least all confirmed smear positive cases. Good case management includes directly
observed therapy during the intensive phase for new sputum smear-positive cases, the
continuation phase of rifampicin-containing regimens and the whole re-treatment
regimen. The mainstay of TB control is organizing and administering standardized
treatment across a country for adult and pediatric TB cases – sputum smear-positive,
smear-negative, and extra-pulmonary. WHO guidelines on patient categorization and
management should be followed. These guidelines emphasize use of the most effective
standardized, short-course regimens, and of fixed-dose drug combinations (FDCs) to
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facilitate adherence to treatment and to reduce the risk of the development of drug
resistance. Separate WHO guidelines are also available for management of patients with
drug-resistant TB. Services for TB care should identify and address factors that may
make patients interrupt or stop treatment. Supervised treatment, which may have to
include direct observation of therapy (DOT), helps patients to take their drugs regularly
and complete treatment, thus achieving cure and preventing the development of drug
resistance. Supervision must be carried out in a context-specific and patient-sensitive
manner, and is meant to ensure adherence on the part both of providers (in giving proper
care and support) and of patients (in taking regular treatment). Depending on the local
conditions, supervision may be undertaken at a health facility, in the workplace, in the
community, or at home. It should be provided by a treatment partner or treatment
supporter who is acceptable to the patient and is trained and supervised by health
services. Patient and peer support groups can help to promote adherence to treatment.
Selected patient groups, for example prisoners, drug users, and some people with mental
health disorders, may need intensive support including DOT. Locally appropriate
measures should be undertaken to identify and address physical, financial, social and
cultural barriers – as well as health system – barriers to accessing TB treatment services.
Particular attention should be given to the poorest and most vulnerable population
groups. Examples of actions that may be appropriate include expanding treatment outlets
in the poorest rural and urban settings, involving providers who practice close to where
patients live, ensuring the services are free or heavily subsidized, offering psychological
and legal support, addressing gender issues, improving staff attitudes, and undertaking
advocacy and communication activities (7-10).
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d)

An effective drug supply and management system. An uninterrupted and

sustained supply of quality-assured anti-TB drugs is essential to control TB. A reliable
system of procurement and distribution of essential anti-TB drugs to health facilities
should be in place. The TB recording and reporting system is designed to provide the
information needed to plan, procure, distribute and maintain adequate stocks of drugs.
Anti-TB drugs should be available free of charge to TB patients. Treatment has benefits
that extend to society as a whole (cure prevents transmission to others). Legislation
related to drug regulation should be in place, and use of anti-TB drugs by providers
should be strictly monitored. The use of FDCs of proven bioavailability and of innovative
packaging such as patient kits can help to improve drug supply logistics as well as drug
administration, promote adherence to treatment and prevent development of drug
resistance. The Global Drug Facility and the Green Light Committee (GLC) offer
countries with limited capacity the benefit of access to quality-assured TB drugs at
reduced prices and also facilitate access to training on drug management (7-10).
e)

A monitoring and evaluation system with impact measurement. A standardized

recording and reporting system is vital for TB control program. This consists of
standardized recording of individual patient data, including information on case detection
and treatment outcomes, which are then used to compile treatment outcome reports in
cohorts of patients. These data, when compiled and analyzed, can be used at the facility
level to monitor treatment outcomes, at the district level to identify local problems as
they arise, at provincial or national level to ensure consistently high-quality TB control
across geographical areas, and nationally and internationally to evaluate the performance
of each country. In addition, regular supervision should be carried out to verify the
35

quality of information and to address performance problems. To enhance recording and
reporting, additional diagnostic information including sputum culture, DST and HIV test
results are needed. These data can be used to guide patient management in both
developed and developing countries. TB program managers also need to monitor records
and reports from public and private care providers not directly linked to the NTP. Special
attention must be paid to ensure the confidentiality of patient information. Making the
best use of data at all levels will mean many countries train staff in the analysis and
interpretation of data, as well as in the use of the computer software that can greatly
facilitate this work. As electronic recording systems become more widely available,
consideration should be given to storing individual patient data, which will make more
detailed analysis of aggregated data possible (7-10). This strategy is an effective case
management system to help ensure patients take quality anti-tuberculosis drugs, at the
right dosage, for the appropriate length of time, and to minimize the development of
resistance by preventing treatment failure. The strategy can be integrated successfully
within general health services to achieve widespread coverage. DOTS does not require
hospitalization or isolation; patients can remain in their homes and return to work in a
few weeks (7-10).
Since the introduction of the DOTS strategy in the early 1990s, considerable
progress has been made in global TB control. As of 2000, 148 countries had adopted the
WHO DOTS strategy for TB control and one fourth of the global TB cases were treated
under DOTS. The report of the Ad-hoc Committee on Tuberculosis Epidemic, convened
by WHO in London in 1998, commended the achievements of a few countries but
expressed concerns about the slow progress of DOTS implementation in most countries
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with a high burden of TB. Identifying the major constraints to DOTS implementation, the
committee recommended a comprehensive and multi-sectored approach to TB control.
Subsequently, in late 1998, a global partnership was launched linking health, social and
economic sectors in the fight against TB. The partnership, called "Stop TB Initiative",
was hosted by WHO. In the year 2000, a high level Ministerial Conference of Ministers
of health and finance of the top 20 high burden countries endorsed the "Stop TB
Partnership" in what is called the "Amsterdam Declaration‖. Global targets for TB
control were also set in 1991 and reaffirmed subsequently (8).
Most government health services now recognize TB control must go beyond
DOTS, but the broader Stop TB Strategy is not yet fully operational in most countries.
According to WHO TB report of 2007, DOTS which underpins the Stop TB Strategy,
was being applied in 187 countries in 2005, or about 90% of the world’s population.
More than 90 million TB patients were reported to WHO between 1980 and 2005; 26.5
million patients were notified by DOTS programs between 1995 and 2005, and 10.8
million new smear-positive cases were registered for treatment by DOTS programs
between 1994 and 2004. A total of 199 countries/areas reported about five million
episodes of TB in 2005 (new patients and relapses); about 2.3 million new pulmonary
smear-positive patients were reported by DOTS programs in 2005; and about 2.1 million
were registered for treatment in 2004. The plans for human resources which are central to
any public health programs made by national TB control programs (NTPs) in 2005-2006
were highly variable in quality. Seven of the 22 HBCs, including five African countries,
had limited plans. NTPs in all WHO regions reported drug stock-outs, few laboratories,
weak quality control, and limited facilities to carry out culture and drug susceptibility
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testing; and many NTPs asked for further technical and financial assistance (80).
Although the number of HIV-positive and multidrug-resistant TB patients diagnosed and
treated was increasing in 2005, numbers were still lower than proposed in the Global Plan
for 2006. The treatment success rate for MDR-TB patients in projects approved by the
Green Light Committee (GLC) was close to 60%, and higher than in non-GLC projects
(21).
Few NTPs have done an overview of TB research in their countries. Although TB
control funds have increased enormously compared to previous years, reaching $ 2.0
billion (US) in 2007, interventions required by the Global Plan to Stop TB would cost an
extra $ 1.1 billion (US) in 2007 (21).
In sum, the WHO TB report of 2007 draws four main conclusions about progress
in TB control, based on routine monitoring and surveillance data from DOTS. First
National TB Programs (NTPs) worldwide narrowly missed the 2005 targets for case
detection (60%/70%) and treatment success (84%/85%). However, both targets were met
in the Western Pacific Region, and in 26 countries including China, the Philippines and
Viet Nam. Second, while the total number of patients diagnosed and treated under DOTS
approached target levels in 2005, the numbers known to be HIV-positive or carrying
drug-resistant bacteria (MDR-TB) were far fewer than anticipated by the Global Plan in
2006. Therefore, a major effort is needed to step up collaborative TB/HIV activities and
the management of MDR-TB. Third, the global TB epidemic appears to be on the
threshold of decline. The incidence rate (per capita) worldwide has evidently stabilized or
begun to fall, following the earlier downturns in prevalence and mortality. The incidence
rate is now stable or falling in all WHO regions, including Africa and Europe. These
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findings, if robust, mean that MDG target 8 was met before 2005, and more than 10 years
before the target date of 2015. However, the total number of new TB cases was still rising
slowly in 2005 in the African, Eastern Mediterranean and South-East Asia regions.
Moreover, in some Asian countries that reporting high rates of case detection and
treatment success, incidence has not apparently been reduced as quickly as expected, for
reasons that are not fully understood. This is linked to the fourth conclusion: the global
TB burden is not yet falling fast enough to satisfy the more demanding targets set by the
Stop TB Partnership within the MDG framework. At the current rate of progress, the
1990 prevalence and mortality rates will not be halved worldwide by 2015 (21). Further
information can be found in Figures 16, and 17 in the appendixes.
DOTS-Plus
High levels of MDR-TB in some areas threaten TB control efforts. DOTS-Plus
for MDR-TB is a comprehensive management initiative, built upon the five elements of
the DOTS strategy. However, DOTS-Plus also takes into account specific issues, such as
the use of second-line anti-TB drugs. The goal of DOTS-Plus is to prevent further
development and spread of MDR-TB. DOTS-Plus is not intended for universal
application. The underlying principle is that the first step in controlling MDR-TB is
prevention by full implementation of DOTS. An effective DOTS-based TB control
program is a prerequisite for implementation of DOTS-Plus (31). In 1999, WHO
established the Working Group on DOTS-Plus for MDR-TB. The Working Group was
renamed in May 2006 to the Stop TB Working Group on MDR-TB. Main achievements
over the last few years in MDR-TB surveillance and control include: coordinating a
network that has surveyed drug resistant TB in almost 100 countries worldwide;
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establishment of an international TB reference laboratory network, consisting of 25
laboratories worldwide for global surveillance and MDR-TB control; establishment of
the Green Light Committee (GLC) mechanism , a multi-institutional partnership to
promote access to life-saving high-quality second-line drugs at reduced prices for the
treatment of MDR-TB and under rigorous monitoring to prevent the creation of resistance
to second-line drugs, the last line of defense against TB. By November 2006, 51 projects
in 40 countries had been approved by the GLC for the treatment of about 25,000 MDRTB patients. The activities of these projects are publishing evidence on feasibility,
effectiveness and cost-effectiveness of MDR-TB management; developing guidelines on
MDR-TB surveillance and management; conducting regional and country level
workshops on MDR-TB, and technical assistance about MDR-TB especially to HBCs;
conducting a project to pre-qualify second-line drug manufacturers and their products
and to develop a list of quality-assured drugs; developing a 10-year strategic plan of the
Working Group which forms part of the Global Plan to Stop TB, 2006-2015; and,
management of MDR-TB as part of the new Strategy to Stop TB and the International
Standards of TB Care (91). Further information is included in Figures 23, and 24 in the
appendixes.
TB/HIV Control
As mentioned previously, TB and HIV are closely interlinked. TB is a leading
cause of HIV-related morbidity and mortality. HIV is the most important factor fuelling
the TB epidemic in populations with a high HIV prevalence. The WHO global strategic
framework to control TB/HIV represents a coordinated response to the joint epidemics of
TB and HIV. Collaboration between TB and HIV/AIDS programs is crucial in supporting
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general health service providers. These providers need support in delivering the full range
of HIV and TB prevention and care interventions. The TB/HIV Working Group of the
Stop TB Partnership was established in 2001 with the aim of coordinating the global
response to the HIV associated TB epidemic. The HIV pandemic presents a massive
challenge to the global control of TB at all levels. However, to counteract the impact of
HIV on TB, other interventions are required apart from effective TB case-finding and
cure. These interventions include measures to decrease HIV transmission (e.g. promotion
of condoms; treatment of sexually transmitted infections; voluntary counseling and HIV
testing; safe and reduced intravenous drug use; reduction in the number of sexual
partners; prevention of mother-to-child HIV transmission; HIV screening of blood for
transfusion; application of universal HIV precautions by health care workers;
antiretroviral therapy (ART) to improve or maintain immune function in people living
with HIV infection; care for people living with HIV infection (e.g. treatment of HIVrelated diseases, prevention of HIV-related infections, TB prevention, palliative care and
nutritional support) (31).
According to WHO recent report on TB, the overall progress of implementation
of collaborative TB/HIV activities, particularly in those countries with greater burden has
been low. The TB/HIV Working Group will review its current strategy and operational
framework to address these gaps, and ensure the delivery of collaborative TB/HIV
activities for patients in need of the services. (92). Additional information is included in
Figure 21 in the appendix.
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Practical Approach to Lung Health (PAL)
PAL is an integrated strategy to manage respiratory patients in primary health
care (PHC) settings with a focus on priority respiratory diseases, particularly TB, acute
respiratory infections, including pneumonia, and chronic respiratory diseases, namely
asthma and chronic obstructive pulmonary disease (COPD). Its objectives are to improve
the quality of respiratory case management and the efficiency of the health system to deal
with respiratory conditions. PAL relies on two pillars to be adapted into the health
environment of a country: a) standardization of the respiratory condition management,
and b) coordination among the relevant bodies to deal with respiratory care services
within each district health system. Some other issues to fully promote PAL include: a)
Price reduction schemes to increase access to medication for chronic respiratory diseases,
especially in developing countries; b) Clear definition and development of the standards
for reliable, affordable, and simple diagnostic equipment; c) Extension of clinical
interventions beyond health facilities to the community level by conducting public health
campaigns to promote respiratory health (93, 94).
Millennium Development Goals
World leaders agreed to a set of time bound and measurable goals and targets
combating poverty, hunger, disease, illiteracy, environmental degradation and
discrimination against women at the United Nations Millennium Summit in September
2000. They are placed at the heart of the global agenda, now called the Millennium
Development Goals (MDGs). The Summit’s Millennium Declaration also outlined a wide
range of commitments in human rights, good governance and democracy. At the
International Conference on Financing for Development in Monterrey, Mexico (2002)
42

leaders from both developed and developing countries started to match these
commitments with resources and action, signaling a global deal in which sustained
political and economic reform by developing countries will be matched by direct support
from the developed world in the form of aid, trade, debt relief and investment. The
MDGs thus provided a framework for the entire UN system to work coherently together
towards a common end. The UN Development Group (UNDG) will help ensure that the
MDGs remain at the centre of those efforts. On the ground in virtually every developing
country, the UN is uniquely positioned to advocate for change, connect countries to
knowledge and resources, and help coordinate broader efforts at the country level. The
world is making progress toward the MDGs, but the majority of nations will reach the
MDGs only if they get substantial support—advocacy, expertise and resources—from
outside. The challenges for the global community, in both the developed and developing
world, are to mobilize financial support and political will, re-engage governments, reorient development priorities and policies, build capacity and reach out to partners in civil
society and the private sector. To achieve MDGs, working on key dimensions such as
practical assistance in support of country priorities, country-level monitoring, global
monitoring, research leadership, and advocacy are essential. MDGs consist of eight
specific aims, which have been expressed in general terms and accompanied by between
one and six specific targets and by several indicators for measurement of progress
towards each of the targets (95). These aims are:
1. Halve extreme poverty and hunger.
2. Achieve universal primary education.
3. Empower women and promote equality between women and men.
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4. Reduce Child mortality: The accompanying target was to reduce the under-five
mortality rate by two-thirds between 1990 and 2015.
5. Improve maternal health. The specific target was to reduce maternal mortality by
three quarters between 1990 and 2015
6. To combat HIV/AIDS, malaria, TB, and other diseases. The two accompanying
targets called for a halt and reversal by 2015 in the spread of diseases or
incidence, especially HIV/AIDS, TB and Malaria. These diseases have erased a
generation of development gains.
7. Ensure environmental sustainability. More than one billion people still lack access
to safe drinking water
8. Create a global partnership for development, with targets for aid, trade and debt
relief.
Although the MDGs are highly relevant for health—in the sense that faster
progress towards any one of them could be expected to produce health gains— three of
them (four, five and six) refer to health explicitly and the sixth to TB (95). Additional
information on MDGs can be found in Figure 17 in the appendix.
The Global Plan to Stop TB 2006-2015 (Stop TB Strategy)
This plan was launched at the World Economic Forum in Davos, Switzerland, in
January 2006, following 18 months of consultation and research by WHO TB experts.
The global plan is for both developing and developed countries so everyone recognizes
their role in fighting the TB epidemic through actions. TB can be overcome if richer
countries step forward and adequately contribute technical and financial assistance, and at
the same time, high burden countries make TB a priority. As preliminary steps in TB
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control have been achieved in recent years, this Plan can further reduce TB burdens (96,
97). Full funding of this new global plan would promote achievement of MDGs; increase
access to quality TB diagnosis and treatment for all; save 14 million lives; treat 50
million TB people; put 3 million TB-HIV co-infected patients on to ARVs; treat nearly
one million people for MDR-TB; help introduce the first new TB drug in four years by
2010; help introduce a new vaccine by 2015; and provide rapid and inexpensive
diagnostic tests at the point of care (96, 97).
The vision of the Stop TB Strategy is a world free of TB. Its goal is to
dramatically reduce the global burden of TB by 2015 in line with MDG 6 and the Stop
TB Partnership targets The objectives are: a) Achieve universal access to high-quality
diagnosis and patient-centered treatment; b) Reduce the human suffering and
socioeconomic burden associated with TB; c) Protect poor and vulnerable populations
from TB, TB/HIV and multidrug-resistant TB; d) Support development of new tools and
enable their timely and effective use. The Stop TB Strategy targets are based on MDG 6,
target 8, ―halted TB burden to half by 2015 and begun to reverse the incidence‖ which is
endorsed by Stop TB Partnership. They are: a) detect at least 70% of new sputum smearpositive TB cases and cure at least 85% of these cases by 2005; b) Reduce prevalence of
and deaths due to TB by 50% relative to 1990 by 2015; c) Eliminate TB as a public
health problem (<1 case per million population) by 2050 (11).
Components of the Stop TB Strategy:
1. Pursue high-quality DOTS expansion and enhancement through: a) political
commitment with increased and sustained financing; b) case detection through qualityassured bacteriology; c) standardized treatment with supervision and patient support; d)
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an effective drug supply and management system; e) monitoring and evaluation system,
and impact measurements.
2. Address TB/HIV, MDR-TB and other challenges by: a) implementing collaborative
TB/HIV activities; b) Prevent and control multidrug-resistant TB; c) and Addressing
prisoners, refugees and other high-risk groups and special situations (11)
3. Contribute to health system fortification by: A) Active participation in efforts to
improve system-wide policy, human resources, financing, management, service delivery,
and information systems; b) Share innovations that strengthen systems, including the
practical approach to lung health (PAL);c) and adapt innovations from other fields (11).
4. Engage care providers with public-public, and public-private mix (PPM) approaches,
and promoting International standards for TB care (ISTC) (11)
5. Empower people with TB, and communities via: a) advocacy, communication and
social mobilization; b) allow community participation in TB care. c) And forming
patients’ charter for tuberculosis care (11).
6. Enable and promote research which is program-based and focus on developing new
diagnostics, drugs and vaccines (11).

TB in WHO Eastern Mediterranean Region (EMR)
There are 22 countries6 in WHO Eastern Mediterranean region, located in North
Africa, Middle East, and Pakistan in Indian sub-continent. These countries differ in terms
of political stability, income, population, climatological and geographical variables. TB is
6

22 countries in WHO East Mediterranean region are; Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq,
Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Oman, Pakistan, Qatar, Saudi Arabia,
Somalia, Sudan, Syrian Arab Republic, Tunisia, United Arab Emirates, West Bank and Gaza Strip, and
Yemen (3).
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an important public health problem in this region. Every year the disease kills about
136,000 people and affects over 630,000 more, fueled by political and economic
instability, migration and displacement, poverty, malnutrition, low coverage of health
services, smoking, HIV/AIDS and drug-resistant strains (12-17). HIV is the most
significant risk factor for progression from LTBI to active TB. Although the HIV/AIDS
threat in the region appears to be relatively modest and so far there has been no evidence
of an impact of HIV on TB epidemiology in the region, there is a need to jointly address
HIV infection and TB more effectively (17).

Figure 2. WHO Eastern Mediterranean Region (EMR) (98)

Since the introduction of the DOTS strategy in mid-1990, most countries have
DOTS program in the Eastern Mediterranean region and strive to expand DOTS services
throughout the network of health facilities of ministries of health to achieve 100%
population coverage as well as high treatment success rates. In 2005, the regional DOTS
coverage was close to 90% and the regional average treatment success rate was about
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84%. There are many middle income countries in the region with a well developed public
health care infrastructure. Political commitment to TB control is generally good. Most
countries have thus laid the foundation for effective TB control. In other words, they have
completed the first stage in the development of TB control, which is to achieve basic
DOTS coverage and good treatment outcomes within the existing programs. A few
countries, such as Morocco and Tunisia, have already achieved the 2005 global targets of
detecting at least 70% of new smear-positive cases and treating successfully at least 85%
of these cases. TB incidence has started to decline in these countries. There is increasing
awareness in the region of the impact of HIV on TB. Initial steps have been taken to
establish HIV surveillance among TB patients and to implement collaborative TB/HIV
activities where appropriate. DOTS-Plus pilot projects have been implemented in Egypt,
Jordan, Lebanon, Syrian Arab Republic and Tunisia, and the Practical Approach to Lung
Health (PAL) strategy has been initiated in Jordan, Morocco, Syrian Arab Republic and
Tunisia (12, 15, 17-19).
There are still many challenges to address in this region. Geographical expansion
of DOTS is incomplete in countries with complex emergencies because of poor health
infrastructure or an unsafe environment, namely Afghanistan, Iraq, Somalia and Sudan
(South and Darfur). The other countries in the region are now in the second stage in the
development of TB control– the stage of further improving quality and access. They are
struggling with low case detection: the regional case detection rate was expected to be
only 45% by the end of 2005. Case detection in the two high-burden countries of the
region – Pakistan and Afghanistan – is still low, at about17% and 18%, respectively, due
to many factors. Key components of DOTS, particularly case-finding and surveillance,
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are not always of high quality. In many countries of the region, the private health care
sector is booming but is not yet involved in DOTS. In addition, important segments of the
public health care sector, such as social security health services or army health services,
are not yet involved. Coverage of drug resistance surveillance is low but is being
expanded. The impact of HIV on TB is becoming increasingly important in countries
with a generalized HIV epidemic (e.g. Djibouti, Somalia, Sudan) and in those where
injecting drug use is an important cause of HIV infection (e.g. the Islamic Republic of
Iran). The challenge will be to implement collaborative TB/HIV activities to address
HIV-related TB in settings where health systems are weak and health service delivery is
complicated by civil conflict. The first priority is to improve further the quality of key
basic components of DOTS, such as laboratory diagnosis, surveillance and drug
management, and to develop and sustain adequate human resources to deliver quality
DOTS. Public-private partnership to provide DOTS should be scaled up widely. The
involvement of the NGO sector will continue to be essential in areas with complex
emergencies. To facilitate implementation of DOTS-Plus, culture and drug susceptibility
testing services should be scaled up (17-20).
DOTS-Plus will be expanded in a stepwise approach to reach 100% coverage by
2015. Scaling up culture services will also improve the diagnosis of smear-negative TB
cases, which is particularly important for areas with high HIV prevalence. To further
improve quality across different health sectors, and help boost case detection, PAL
should also be implemented widely in the region, community DOTS should be scaled up
in selected rural areas. Collaborative TB/HIV activities need to be implemented and
strengthened in settings with a high HIV burden. Operational research activities should
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be continued to solve problems identified through the TB surveillance and TB control
information system (17-20).
Countries in the Eastern Mediterranean region should be supported in adapting,
developing and implementing special strategies to control TB, especially in poor settings
and in big cities. To realize sustainable political, technical and financial support to TB
control, Stop TB Partnerships should be developed at regional and national levels, and
strategic approaches for communication, advocacy and social mobilization should be
adapted and implemented. Successful implementation of the activities described above is
expected to increase case detection rapidly to 73% by 2010 and 80% by 2015; treatment
success rate is expected to increase from 84% to 87% in 2010 and then it be sustained at
this level. TB incidence, prevalence and death rate are already falling in the region;
moreover, planned activities are predicted to boost the decline further, so the 2015
Partnership targets, linked to the MDG target, will be met in the Eastern Mediterranean
region. During the period of the plan (2006–2015), it is estimated that 3.6 million people
will be treated under DOTS programs and 48 000 under DOTS-Plus. In addition, 36 000
TB patients will be enrolled on antiretroviral therapy. The combined effect of all
interventions will be to prevent about 798 000 deaths, about four times as many as where
no DOTS programs are implemented, or about 196 000 deaths in comparison with a
situation in which TB control efforts are sustained at 2005 levels. The total estimated cost
of DOTS expansion, DOTS-Plus and TB/HIV control activities in the Eastern
Mediterranean region from 2006 to 2015 is about $2.6 billion (US) (12, 13, 15, 17-20,
99). Additional information is included in Table 9 in the appendix.
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CHAPTER III
METHODS AND PROCEDURES
The primary objective of this study was to identify and describe the progress and
barriers of TB control programs in 22 EMR countries of WHO toward MDGs and 1991
National Health Assembly targets for DOTS. Also, the study explored the relationship
between TB burden (morbidity and mortality) and DOTS in EMR countries and
following variables: political stability, population density, GDP, income, healthcare
force, health expenditure, HIV prevalence, immunization coverage, sanitation, adult
literacy rate, adult smoking rate, national poverty level and malnutrition. The research
specific questions were:


Has the Eastern Mediterranean region made any progress towards achieving
MDGs and DOTS?



How is TB/HIV co-morbidity in the region?



Are there relationships between TB burden and DOTS in EMR countries and
sociopolitical variables?



What are some of the data gaps, challenges and accomplishments to be used as
lessons for future interventions?

Data Sources
TB data (incidence, prevalence, death, DOTS coverage, treatment, TB-HIV coinfection), world health statistics, and health human resources data were publicly
available from WHO Global Health Atlas from 1980 to 2005 and were retrieved for use
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in this study. Other demographic, political, and socioeconomic variables were retrieved
from World Bank and World Resource Institute (100) online databases as well as the
American Cancer Society (101) webpage.
WHO’s Communicable Disease Global Atlas is a single platform that brings
together for analysis and comparison standardized data and statistics for infectious
diseases at country, regional, and global levels. The analysis and interpretation of data are
further supported through information on demography, socioeconomic conditions, and
environmental factors. In so doing, the Atlas specifically acknowledges the broad range
of determinants that influence patterns of infectious disease transmission. The system
aims to provide a single point of access to data, reports and documents on the major
diseases of poverty including malaria, HIV/AIDS, and tuberculosis, as well as the
diseases on their way towards eradication and elimination, but yet prone to epidemics
such as meningitis, cholera, and yellow fever. Anti-infective drug resistance and
emerging infections are covered as well. The database is updated on an ongoing basis and
in addition to epidemiological information, the system aims to provide information on
essential support services such as the network of communicable diseases collaborating
centers, the activities of the Global Outbreak Alert and Response Network, etc.
WHO collects TB data annually from NTPs or relevant public health authorities
in 212 countries via a standard data collection forms which are used to compile
aggregated national data. The process of national and international reporting is distinct
from WHO’s recommendation about procedures for recording and reporting data by
NTPs within countries, from district level upwards. Completed forms are collected and
reviewed at all levels of WHO: country offices, regional offices and at headquarters. An
52

acknowledgement form that tabulates all submitted data is sent back to the NTP
correspondent to complete any missing responses and to resolve any inconsistencies.
Then using the complete set of data for each country, a constructed profile tabulating all
key indicators, including epidemiological data, and financial data, is estimated and
returned to each NTP for review (21, 102).
Earth Trends, an online database, was launched in 2001 by the World Resource
Institute (100) based in Washington DC. Earth Trends gathers data from the world’s
leading statistical agencies, along with WRI-generated maps and analysis into a single
database. These resources are made available to the public at no charge. Inside this
researchable database, there is time –series information for over 600 variables, more than
200 country profiles, as well as data tables, maps, and feature stories on a variety of
environmental, social, and economic topics (100).
World Bank Governance Indicators (WGI) reports aggregate and individual
governance indicators for 212 countries and territories over the period 1996–2006. The
aggregate indicators combine the views of a large number of enterprise, citizen and
expert survey respondents in industrialized and developing countries. The individual data
sources underlying the aggregate indicators are drawn from a diverse variety of survey
institutes, think tanks, non-governmental organizations, and international organizations
(103). World Development Indicators Online (104) provides direct access to more than
700 development indicators, with time series for 208 countries and 18 country groups
from 1960 to 2006. Most social data are collected annually. Some economic and financial
data are available on monthly or quarterly basis. The World Bank also publishes annual
socio-economic data in its data publications and on its web site (103-105).
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The Tobacco Atlas, second edition published by American Cancer Society (101)
and the International Union Against Cancer (IUAC) in 2006, maps distinct features of the
tobacco pandemic, including prevalence, mortality, trade, smuggling, and research (101).
Ethical Considerations
The data were retrieved from publicly available on line databases, and no contact
was made with any entities. However, the Institutional Review Board (IRB) at Georgia
State University (GSU) approved the research methods, and granted exempted status. The
approved protocol number was 00000129 (see Appendix A).
Quality of data
As mentioned, the data were retrieved from WHO, WB, WRI and ACS. TB
detected under DOTS/2003 and TB successful treatment rate under DOTS 2002 of WHO
TB database and WHO World Health Statistics database were compared to investigate
data quality. For a few countries, the first variable was quite different. The second
variable was similar in both databases except for Yemen. West Bank and Gaza data were
missing in the World Health Statistics. Based on a comparison of particular values in
these databases, the quality of data is under question because the same variable value was
not only different in different organization databases, but it may also have been different
in the same organization’s databases. In addition, there were a number of missing values
for some variables. Variables used in this study and their respective sources are noted in
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Table 1. List of variables with their respective sources
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Variable
Eastern Mediterranean Region Countries
Whole country new smear-positive case detection rate (%)
DOTS new smear-positive case detection rate (%)
DOTS population coverage (%)
New and relapse cases (per 100 000 population)
DOTS treatment success (%) -> Total
Non-DOTS treatment success (%) -> Total
TB incidence, all forms (per 100 000 population per year) -> Total
TB incidence, all forms in HIV+ adults (per 100 000 population per
year) -> Total
TB prevalence, all forms in HIV+ adults (per 100 000 population per
year) -> Total
TB prevalence, all forms (per 100 000 population per year) -> Total
TB mortality, all forms in HIV+ adults (per 100 000 population per
year) -> Total
TB mortality, all forms (per 100 000 population per year) -> Total
Sanitation access coverage -> Rural
Sanitation access coverage -> Urban
General government expenditure on health -> Total
Total number of health workers per 10000 population -> Total
Adult literacy rate -> Total
Income per capita
Political Stability and Absence of Violence Index
GDP, current US dollars
Immunization rate for tuberculosis in one-year-olds
Population
Access to improved sanitation
Adults and children living with HIV
Physicians per 100,000 people
National poverty rates
Underweight children under 5--moderate and severe %
Literacy rate, all adults %
Population density per square kilometer
Adult smoking prevalence %
Malnutrition
Per capita total expenditure on health (int'l dollar rate) -> Total

1

years

Source

1995-2005
1995-2005
1995-2005
1980-2005
1994-2004
1994-2004
1990-2005
1990-2005

WHO1
WHO
WHO
WHO
WHO
WHO
WHO
WHO

1990-2005

WHO

1990-2005
1990-2005

WHO
WHO

1990-2005
2002
2002
1998-2002
1997, 2001-2003
2005
2006
1996-2006
1990-2005
2005
1980-2008
1990, 2004
2003, 2005
1990-2004 (one)
1987-2004 (one )
1996-2005 (one)
2000-2004 (one)
1980-2008
2006
2001-2006
1998-2002

WHO
WHO
WHO
WHO
WHO
WHO
WDI2
WGI3
WRI4
WRI
WRI
WRI
WRI
WRI
WRI
WRI
WRI
WRI
ACS5
WDI
WHO

World health organization (WHO), 2World Development Indicators (WDI), 3World Bank Governance
Indicators (WGI), 4World Resource Institute (WRI), 5 American Cancer Society (ACS)
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Statistical Analyses
Data were retrieved from WHO, WB, WRI and ACS Tobacco Atlas. After
cleaning, entering, and merging data from aforementioned sources, SPSS (version 15)
and Microsoft Excel were used for data analysis. Data analyses were conducted in three
categories;
a) TB data trends over period of time. Microsoft Excel was used to create graphs.
Paired Samples t-tests were used to test for significant change over time. In the data
tables, zero (0) means no report where not applicable (N/A) or dot (.) means missing
value.
b) TB data comparison; Microsoft Excel was used to draw comparison graphs and
Paired Samples t-tests were used to show test of significance for two variables at the
entire period as well as at the beginning and at the end of the period. As there were lots of
missing values, the mean of data were computed in two periods of time for a variable to
show comparison at the beginning (before 2000) and at the end (2000-2005).
c) Comparison of TB burden and DOTS data with different demographic,
socioeconomic, health and political variables. The data were not available for all
variables during the entire period; one variable data was available for more than 20 years
whereas other one existed for only one year. To solve this problem, the mean of data for
2000-2006 was computed for each variable. Also data were available in different
databases with differences in values and time (2000-2006), so the mean of them were
computed to fill the gap of missing value and time differences. Data with more than two
categories and data with minus and plus values were computed to dichotomous variables.
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Bivariate correlation was used to explore the association of dependent variable (TB
burden and DOTS) with independent variables (different continuous variables).
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CHAPTER IV
RESULTS
The primary objective of this study was to identify and describe the progress and
barriers of TB control programs in 22 EMR countries of WHO toward MDGs and 1991
National Health Assembly targets for DOTS. Also, the study sought to describe the
TB/HIV co-morbidity situation and the relationships of TB burden (incidence, prevalence
and mortality) and DOTS with sociopolitical variables.
Comparison of TB burden and DOTS data trend (1990-2005)
The first research question focused on whether the EMR has made progress
toward MDGs to reduce TB burden and to reverse TB incidence. The progress in this
region was assessed by comparing values from 1990 or 1994/95 to values from 2005 or
2004, using a paired-t test. The results for variables related to TB burden and DOTS are
summarized in Table 2.
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Table 2. Comparison of TB burden (incidence, prevalence, and mortality) and DOTS between 1990 and 2005.
Beginning

Ending

95% CI

Mean

Variable

Sig. (2SD

Mean

Mean

difference

Lower

Upper

df
tailed)

TB incidence, all forms (per 100 000 population per year) ->
Total/ 1990 & 2005

107

97.3

9.7

-12.2

31.6

49.4

21

0.37

TB incidence, all forms in HIV+ adults (per 100 000
population per year) -> Total/1990 &2005

0.6

6.8

-6.2

-16.8

4.3

19.1

14

0.23

TB prevalence, all forms (per 100 000 population per year) ->
Total/ 1990 &2005
TB prevalence, all forms in HIV+ adults (per 100 000
population per year) -> Total/1990 &2005
TB mortality, all forms (per 100 000 population per year) ->
Total/ 1990 &2005

227.8

143.3

84.5

24.5

144.6

135.5

21

0.01

0.3

3.4

-3.1

-8.4

2.2

9.5

14

0.23

23.6

16.9

6.7

-0.9

14.2

17

21

0.08

TB mortality, all forms in HIV+ adults (per 100 000
population per year) -> Total/ 1990 & 2005
DOTS population coverage (%)/1995 &2005

0.3

2.1

-1.8

-4.7

1.05

5.2

14

0.2

46.1

99.1

-53

-92.3

-13.7

47

7

0.02

Whole country new smear-positive case detection rate
(%)/1995 & 2005

49.4

60.8

-11.4

-25.3

2.5

27.1

16

0.10

DOTS new smear-positive case detection rate (%)/1995 &2005

45.1

61.2

-16.1

-36.7

4.4

24.6

7

0.11

DOTS treatment success (%) -> Total/1994 & 2005

79

82

-3

-12.2

6.2

8.8

5

0.44
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TB incidence, all forms had been reduced 9% in EMR between 1990 and 2005.
As noted in Table 2, the average decrease for a country was about 10 cases per 100 000.
This decline was not statistically different from 0 (Table 2). For the entire region
(countries reporting), TB incidence all forms in HIV+ adults increased from 8 to 102 per
100,000 populations during this period. Although not statistically significant, the average
country increase was 6 cases per 100 000. The trends (Figure 3) show that except for DJI
and SDN, all the countries had decreased TB incidence in this period. It is worth noting
that LBN, JOR, and OMN had reduced TB incidence, all forms over 50% in this period.
PAK and IRQ had had the same TB incidence rates during the entire period. Furthermore,
TB incidence all forms in HIV+ adults was increased in DJI, SOM, and SDN. Further
information is included in Table 10 and Figure 9 in the appendixes.
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Figure 3. TB incidence in WHO Eastern Mediterranean Region, for 1990 to 2005 by
year
MDGs target for TB prevalence was to reduce it by 50% in 2005. Between 1990
and 2005, TB prevalence had reduced 37% for the entire region. As noted in Table 3, the
average decrease for countries in this region was approximately 84 cases per 100 000
representing a statistically significant drop in the average number of cases (p<.05). TB
prevalence all forms in HIV+ adults increased from a total of 4.2 cases per 100 000 in the
region in 1990 to 50.4 in 2005. The average increase at the country level was 3.1. As
shown in Figure 4, all countries show a decrease in TB prevalence between 1990 and
2005. AFG, BAR, JOR, KWT, LBN, LBY, OMN, SOM, and SYR reduced TB
61

prevalence 50% or over 50% in this period. The reasons in AFG may be related to
interventions such as DOTS, increased access to basic health services ( 9% of total
population had access to basic health services in 2001 and according to AFG ministry of
public health, it increased to 65% in 2007), and community participation. The data in
SOM also shows an increase in health expenditure and increase in DOTS population
coverage. Though DJI showed a decrease in the TB prevalence rate, but it was still the
country with the highest rate in 2005. In terms of co-morbidity with HIV, TB prevalence,
all forms in HIV+ adults has increased in DJI, SDN and SOM during this period. Table
11 and Figure 10 in the appendixes provide more information about TB prevalence trends
in EMR between 1990 and 2005.
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Figure 4. TB prevalence in WHO Eastern Mediterranean Region, for 1990-2005 by
year
MDGs target for TB mortality was to show a decrease of 50% in 2005. The
results show that TB mortality, all forms per 100,000 populations in the WHO Eastern
Mediterranean Region, had decreased 28% between 1990 and 2005. This decrease in
country level is 9 deaths, which is not statistically significant (Table3). In EMR, TB
mortality all forms in HIV+ adults had increased from 4.5 in 1990 to 31.5 in 2005 which
is 2 deaths at the country level. Most countries showed a decreasing trend in TB mortality
between 1990 and 2005 (Figure 5), KWT, LBN, LBY, OMN, SOM, and SYR reduced
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TB mortality all forms 50% or over 50%. TB mortality all forms in DJI and SDN
increased. TB mortality all forms in HIV+ adults had increased in DJI, SDN and SOM
during this period. Table 12 and Figure 11 in the appendixes provide more information
about TB mortality trend in EMR for 1990 and 2005 by year.

Figure 5. TB mortality in WHO Eastern Mediterranean Region, for 1990-2005 by
year
DOTS population coverage had increased 77 times in the whole region. As noted
in Table 3, DOTS population coverage for specific countries (n=7) in the EMR region
increased from 46% in 1995 to 99% in 2005. This represents a statistically significant
increase (p=.02). In 2005, all the EMR countries except ARE, AFG and IRQ had DOTS
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population coverage over 90%. Figure 6 and Table 13 in the appendices provide more
information about DOTS population coverage in EMR during 1995 and 2005.

Figure 6. DOTS population coverage in WHO Eastern Mediterranean Region, for
1995-2005 by year
The 1991 National Health Assembly target for DOTS new smear-positive case
detection rate was 70% by 2005. The result shows that DOTS new smear-positive case
detection rate increased 45 times in the region between 1995 and 2005, which is 16% at
the country level; however, this increase was not statistically significant (Table 2). In
2005, LBY, MAR and OMN had over 100% DOTS new smear-positive case-detection
rates whereas DOTS new smear- positive case detection rates were lower in WBG (2%),
ARE (19%) and SDN (35%). Figures 7, 12 and Table 14 in the appendices provide
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further information about TB new smear-case detection rates in EMR during 1995 and
2005.

Figure 7. TB new smear-positive case detection rates in WHO Eastern
Mediterranean Region, for 1995-2005 by year
The 1991 National Health Assembly target for DOTS treatment success rate was
85% by 2005. The result shows that DOTS treatment success in the EMR region had
increased 58 times in 2004. On average, there was a 3% increase per country which was
not statistically significant (Table 2). All countries in the region show an increase in
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DOTS treatment success. Figures 8, 13 and Table 15 in the appendices provide more
information about DOTS treatment success in EMR.

Figure 8. DOTS and Non-DOTS treatment success in WHO Eastern Mediterranean
Region, for 1994-2004 by year
TB burden comparison with TB/HIV co-morbidity rates (1990-2005)
The second research question focused on the TB/HIV co-morbidity situation in
the EMR region. TB burden all forms was compared with TB burden all forms in HIV+
adults per 100,000 populations. Graphical methods and paired samples t-tests were used
to compare the two variables over the entire period as well as at the beginning and at the
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end of the period, respectively. Because of the number of missing values over the time
period, the mean of data were computed in two periodic times for a variable to show
comparison at the beginning (1990- 2000) and at the end (2000-2005). Table 3
summarizes the results of paired samples t-tests used to compare TB burden all forms
with TB burden all forms in HIV+ adults per 100,000 populations.
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Table 3. Comparison of TB Burden (incidence, prevalence and mortality), all forms with TB burden, all forms in HIV+
adults per 100,000 populations between 1990 and 2005.

Variable

TB incidence, all forms with TB incidence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-2005
TB incidence, all forms with TB incidence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-1999
TB incidence, all forms with TB incidence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/2000-2005
TB prevalence, all forms with TB prevalence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-2005
TB prevalence, all forms with TB prevalence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-1999
TB prevalence, all forms with TB prevalence, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/2000-2005
TB mortality, all forms with TB mortality, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-2005
TB mortality, all forms with TB mortality, all forms in
HIV+ adults (per 100 000 population per year) ->
Total/1990-1999

First

Sec.

Variable

Variable

Mean

Mean

134.6

4.4

136.8

Mean

95% CI

Sig. (2-

Lower

Upper

s.d.

130.2

41.1

219.2

160.8

14

0.007

3.2

133.6

46.2

220.9

157.8

14

0.005

130.9

6.5

124.4

32.1

216.9

166.8

14

0.012

239.5

2.2

237.3

66.6

406.0

304.6

14

0.009

263.9

1.5

262.4

78.7

446.0

331.6

14

0.008

198.8

3.3

195.5

50.3

340.8

262.2

14

0.012

27.6

1.4

26.2

8.3

44.1

32.4

14

0.007

29.4

1.1

28.3

8.9

47.6

34.9

14

0.007
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difference

df
tailed)

TB mortality, all forms with mortality, all forms in HIV+
adults (per 100 000 population per year) -> Total/20002005

24.5

1.8

70

22.7

6.6

38.7

28.9

14

0.009

The difference between TB burden (incidence, prevalence and mortality), all forms with
TB burden, all forms in HIV+ adults per 100,000 population was much at the beginning and it
lessened in 2005 which suggests that TB/HIV co-morbidity had gradually increased in the
region. It should be mentioned that this difference was statistically significant during the entire
period (Table 3). Figures 3-5, Figures 9-11, and Tables 10-12 provide further information
about this comparison in EMR.
DOTS comparison with Whole country new-smear positive case detection rate and NonDOTS treatment success rates (1995-2005)
DOTS data were compared with Whole country new-smear positive case
detection rates and Non-DOTS treatment success rates. Graphs and paired samples t-tests were
used to compare the two variables for the entire period as well as at the beginning and at the
end of the period. Because of the number of missing values over the time period, the mean was
computed for two periodic times for the purpose of comparison of the beginning (1994- 2000)
and end (2000-2005) of the period. Table 4 summarizes the results of paired samples t-tests to
compare DOTS data with Whole country new-smear positive case detection rates and NonDOTS treatment success rates.
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Table 4. Comparison of DOTS new-smear positive case detection and treatment success rates with Whole country newsmear positive case detection rate and Non-DOTS treatment success rate, 1995-2005
First
Variable

Whole country new smear-positive case detection rate

variable

Sec.
variable

95 CI

Mean
difference

Lower

Upper

Sig. (2s.d.

df
tailed)

Mean
57.1

Mean
52.9

4.2

-1.1

9.5

11.9

21

0.12

61.2

48.8

12.4

-2.1

26.8

30.9

19

0.09

56.9

56.5

0.4

-0.1

0.9

1.3

21

0.13

78.9

71.5

7.4

-2.1

16.9

19.1

17

0.12

75.6

67.8

7.8

-0.7

16.2

15.9

15

0.07

82.4

66.9

15.5

-1.7

32.7

10.8

3

0.07

(%)/1995-2005 - DOTS new smear-positive case
detection rate (%)/1995-2005
Whole country new smear-positive case detection rate
(%)/1995-1999 - DOTS new smear-positive case
detection rate (%)/1995-1999
Whole country new smear-positive case detection rate
(%)/2000-2005 - DOTS new smear-positive case
detection rate (%)/2000-2005
DOTS treatment success (%) -> Total/1994-2004 - NonDOTS treatment success (%) -> Total/1994-2004
DOTS treatment success (%) -> Total/1994-1999 - NonDOTS treatment success (%) -> Total/1994-1999
DOTS treatment success (%) -> Total/2000-2004 - NonDOTS treatment success (%) -> Total/2000-2004
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In 1995, there was a 22% difference between Whole country (38%) and DOTS
(16%) new smear-positive case detection rates in the region. DOTS new smear-positive
case detection rate increased tremendously to 61% and there was only a 1% difference
with Whole country new smear-positive case detection rate (62%) in 2005. The result of
paired sample t-tests shows the average country difference was 4.2 which was not
statistically significant during the entire period (Table 4). Tables 14, Figures 7, and 12
also provide information about mentioned difference.
As a whole in the region, DOTS treatment success rate was 3 times lower than
Non-DOTS in 1994, but it increased remarkably and it was 63 times higher than NonDOTS in the region by 2004. As noted in Table 4, the average difference between DOTs
and Non-DOTS treatment success rate was 7.4 for the entire period which was not
statistically significant. Figures 8, 13 and Table 15 also provide information about DOTS
and Non-DOTS treatment success comparison.

TB burden and DOTS comparison with some sociopolitical variables (2000-2006)
The final research question focused on the exploration of associations between TB
burden and DOTS and specific sociopolitical variables in EMR countries. Data was not
available for all variables during the entire period. For example, one variable had data available
for more than 20 years whereas another variable had data for only one year. To solve this
problem, the mean of all data for 2000-2006 was computed. Also, the same data was available
in different databases with some differences in values and time (2000-2006), so the mean of
them was computed to fill the gap of missing values and time differences. Income per capita
variable with more than two values and political stability with minus and plus values were
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recoded to dichotomous variables. Bivariate correlations were used to explore the association
of the dependent variable (TB burden and DOTS) with independent variables.
Table 5. Association of TB incidence with some demographic, health, socio-economic and
political variables
Spearman's

Sample

Sig. (2-

rho

size

tailed)

Variable

DOTS population coverage (%)/2000-2005

-.090

22

.690

Adult smoking prevalence %/ 2006

.195

21

.397

Adult Literacy Rate total (%)/ 2000-2005

-.620**

19

.005

National poverty rates/1987-2004

.771

6

.072

Physicians per 100,000 people/ 1990-2004

-.747**

21

.000

Immunization rate for tuberculosis in one-year-olds/2005

-.699**

18

.001

Malnutrition/ 2001-2006

.669**

22

.001

Population density per square kilometer/2000-2006

-.119

22

.597

Income per capita/2006

-.094

22

.677

Political Stability and Absence of Violence Index/2000-2006

-.385

22

.077

Total number of health workers per 100 000 population ->
Total/2001-2003

-.623**

20

.003

General government expenditure on health -> Total/2000-2002

-.287

21

.207

GDP, current US dollars/2000-2005

-.132

21

.567

Access to improve sanitation (%)/2002-2004

-.635**

21

.002

Adults and children living with HIV/ 2003-2005

.154

13

.615

The dependent variable is TB incidence all forms per 100,000 populations
**p<.01

The results of bivariate correlation analysis (Table 5) shows that TB incidence has
a positive relationship with malnutrition, national poverty level (NPL), HIV and adult
smoking rate (ASR). The associations between TB incidence and malnutrition (r s=.67,
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p<.01) and TB incidence and national poverty level (r s=.77, p=.07) were relatively
strong. As the malnutrition rate increases and as NPL increases, TB incidence per
100,000 population increases.
Adult literacy rate (ALR), total number of health workers and physicians, access
to improved sanitation, gross domestic product (GDP), general government expenditure
on health, TB immunization, income per capita, political stability, DOTS population
coverage and population density have an inverse association with TB incidence within a
county. As ALR increases, TB incidence decreases (r s =-.62, p=.005). An increase in
total number of physicians (r s =-.75, p<.001) is associated with decreases in TB
incidence and an increase in total number of health workers is associated with a decrease
in TB incidence (r s =-.62, p<.01). Access to improved sanitation is associated with
decreased TB incidence (r s =-.64, p<.01). Although not statistically significant, GDP and
general government expenditure on health seems to be associated with lower TB
incidence within a country. Higher BCG immunization rates are associated with lower
TB incidence (r s =-.70, p<.01). In addition, there appears to be a moderate negative
association between TB incidence and political stability (r s =-.39, p=.077).
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Table 6. Associations between TB prevalence and some demographic, health, socioeconomic and political variables.
Spearman's

Sample

Sig. (2-

rho

size

tailed)

Variable

DOTS population coverage (%)/2000-2005

-.200

22

.373

Adult smoking prevalence %/ 2006

.216

21

.348

Adult Literacy Rate total (%)/ 2000-2005

-.594**

19

.007

National poverty rates/1987-2004

.886*

6

.019

Physicians per 100,000 people/ 1990-2004

-.718**

21

.000

Immunization rate for tuberculosis in one-year-olds/2005

-.687**

18

.002

Malnutrition/ 2001-2006

.685**

22

.000

Population density per square kilometer/2000-2006

-.092

22

.684

Income per capita/2006

-.094

22

.677

Political Stability and Absence of Violence Index/2000-2006

-.385

22

.077

Total number of health workers per 100 000 population ->
Total/2001-2003

-.642**

20

.002

General government expenditure on health -> Total/2000-2002

-.251

21

.272

GDP, current US dollars/2000-2005

-.160

21

.489

Access to improve sanitation (%)/2002-2004

-.637**

21

.002

Adults and children living with HIV/ 2003-2005

.225

13

.460

The dependant variable is TB prevalence per 100,000 populations
** p<.01
* p<.05.

Table 6 contains the results of the bivariate correlation analysis of TB prevalence
with sociopolitical variables. As might be expected, the results are very similar to those
for incidence. TB prevalence was positively associated with malnutrition, national
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poverty level (NPL), HIV and adult smoking rate (ASR). Higher malnutrition rates, were
associated with higher TB prevalence (r s =.69, p<.001). Increases in NPL were
associated with increases in TB prevalence (r s =.89, p<.05).
Adult literacy rate (ALR), total number of health workers and physicians, access
to improved sanitation, gross domestic product (GDP), general government expenditure
on health, BCG immunization, income per capita, political stability, DOTS population
coverage and population density have an inverse relationship with TB prevalence. As
ALR increases, TB prevalence decreases (r s =-.59, p<.01). A higher number of
physicians per 100,000 population is associated with lower TB prevalence (r s =-.72,
p<.001) and a higher total number of health workers is associated with lower TB
prevalence (r s =-.64, p<.01). Access to improved sanitation is associated with decreased
TB prevalence (r s =-.64, p<.01). A higher BCG immunization rate is associated with
decreased TB prevalence (r s =-.69, p<.01). TB prevalence shows evidence of an
association with political stability (r s =-.39, p=.077) with more stable countries having
lower TB prevalence.
Table 7 shows the results of bivariate correlation analyses for TB mortality and
sociopolitical variables. These results suggest that TB mortality has a positive
relationship with malnutrition, national poverty level (NPL), HIV and adult smoking rate
(ASR). Similar to previous results, as malnutrition rate increases TB mortality increases
(r s =-.69, p<.001). Increases in NPL are also associated with increases in TB mortality (r
s =-.89,

p<.05).
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Table 7. Association between TB mortality and some demographic, health, socioeconomic and political variables.
Spearman's

Sample

Sig. (2-

rho

size

tailed)

Variable

DOTS population coverage (%)/2000-2005

-.469*

22

.028

Adult smoking prevalence %/ 2006

.244

21

.287

Adult Literacy Rate total (%)/ 2000-2005

-.594**

19

.007

National poverty rates/1987-2004

.886*

6

.019

Physicians per 100,000 people/ 1990-2004

-.739**

21

.000

Immunization rate for tuberculosis in one-year-olds/2005

-.726**

18

.001

Malnutrition/ 2001-2006

.686**

22

.000

Population density per square kilometer/2000-2006

-.123

22

.587

Income per capita/2006

-.120

22

.595

Political Stability and Absence of Violence Index/2000-2006

-.411

22

.058

Total number of health workers per 100,000 population ->
Total/2001-2003

-.670**

20

.001

General government expenditure on health -> Total/2000-2002

-.285

21

.210

GDP, current US dollars/2000-2005

-.133

21

.567

Access to improve sanitation (%)/2002-2004

-.649**

21

.001

Adults and children living with HIV/ 2003-2005

.462

13

.112

The dependant variable is TB mortality per 100,000 populations
** p<.01
* p<.05.

Adult literacy rate (ALR), total number of health workers and physicians, access
to improved sanitation, general domestic product (GDP), general government expenditure
on health, BCG immunization, income per capita, political stability, DOTS population
coverage and population density per 100,000 have inverse relationships with TB
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mortality. As ALR increases TB mortality decreases (r s =-.59, p<.01). Increases in total
number of physicians per 100,000 population is associated with decreases in TB
mortality (r s =-.74, p<.001) and a higher total number of health workers is associated
with lower TB mortality (r s =-.67, p=.001). Again, greater access to improved sanitation
is associated with lower TB mortality (r s =-.65, p=.001). A higher BCG immunization
rate is also associated with lower TB mortality (r s =-.73, p=.001). TB mortality appears
to be lower in stable countries compared with unstable countries (r s =-.41, p=.058).
Higher DOTS population coverage is associated with lower TB mortality (r s =-.47,
p=.028). Population density has a weak and no significant negative association with TB
mortality in this region.
Table 8 shows the results of the bivariate correlation analysis for DOTS
population coverage and sociopolitical variables. DOTS population coverage has an
inverse relationship with malnutrition, HIV, national poverty level (NPL) and adult
smoking rate (ASR). Higher malnutrition rates are associated with lower DOTS
population coverage (r s =-.70, p<.001). Higher NPL is also associated with lower DOTS
coverage (r s =-.78, p=.069).
Adult literacy rate (ALR), total number of health workers, number of physicians,
access to improved sanitation, general government expenditure on health, BCG
immunization have a positive relationship with DOTS. Higher ALR is associated with
higher DOTS coverage (r s =.65, p<.01). A higher total number of physicians per 100,000
population is associated with higher levels of DOTS coverage (r s =.44, p<.05) and a
higher total number of health workers is associated with greater DOTS coverage (r s =.54,
p<.05). Greater access to improved sanitation is associated with higher levels of
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Table 8. Association between DOTS population coverage and some demographic,
health, socio-economic and political variables.
Spearman's

Sample

Sig. (2-

rho

size

tailed)

Variable

Adults and children living with HIV/ 2003-2005

-.378

13

.203

Adult smoking prevalence %/ 2006

-.118

21

.610

Adult Literacy Rate total (%)/ 2000-2005

.648**

19

.003

National poverty rates/1987-2004

-.778

6

.069

Physicians per 100,000 people/ 1990-2004

.440*

21

.046

Immunization rate for tuberculosis in one-year-olds/2005

.450

18

.061

Malnutrition/ 2001-2006

-.696**

22

.000

Population density per square kilometer/2000-2006

.209

22

.351

Income per capita/2006

.129

22

.567

Political Stability and Absence of Violence Index/2000-2006

.129

22

.567

Total number of health workers per 100,000 population ->
Total/2001-2003

.543*

20

.013

General government expenditure on health -> Total/2000-2002

.293

21

.197

GDP, current US dollars/2000-2005

-.084

21

.716

Access to improve sanitation (%)/2002-2004

.469*

21

.032

The dependant variable is DOTS population coverage
** p<.01
* p<.05.

DOTS coverage (r s =.47, p<.05). Although not statistically significant, higher
general government expenditure on health is associated with greater DOTS coverage (r s
=.29, p=.197). Higher BCG immunization rates are associated with higher DOTS
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coverage (r s =.45, p=.061) . DOTS population coverage has a positive and weak
association with population density per 100,000 and political stability.
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CHAPTER V
DISCUSSION
The objective of this study was to determine TB progress in the WHO Eastern
Mediterranean Region (EMR) toward MDGs of halting global TB burden (prevalence
and death rate) by 50% in 2015 and to eliminate TB by 2050 compared with 1990. Also,
the study explored the progress toward the 1991 44th World Health Assembly targets for
DOTS to detect at least 70% of new sputum smear-positive TB cases, and to cure 85% of
reported TB cases by 2005 (11). Finally, the study was designed to explore the potential
associations of TB burden and DOTS population coverage with some demographic,
health, socio-economic and political factors.
TB incidence, all forms has decreased about 9 % in the WHO EMR during the
time from 1990 to 2005 which is about a 10 case decrease for individual countries.
However, TB incidence, all forms in HIV+ adults has increased during this same time
period. TB prevalence, all forms has decreased 37% per 100,000 populations in the
region which is an 84 case decrease in each country of the region. However, TB
prevalence, all forms in HIV+ adults has increased during the time period from 1990 to
2005. While TB mortality has decreased by 28% between 1990 and 2005, TB morality all
forms in HIV+ adults has dramatically increased in the region. TB incidence, all forms,
and TB mortality, all forms in DJI and SDN had increased during this period. PAK and
IRQ had constant TB incidence, all forms rates between 1990 and 2005. It is worth
noting that LBN, and OMN reduced TB burden all forms, and JOR reduced TB incidence
and prevalence more than 50% in the region in this period. KWT, LBY, SOM, and SYR
reduced TB prevalence and mortality all forms more than 50% between 1990 and 2005.
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AFG and BAR reduced TB prevalence over 50% in this period. TB/HIV co-morbidly and
mortality has increased between 1990 and 2005 especially in three countries (DJI, SOM
and SDN).
In sum, the WHO EMR as a region had declined TB burden, all forms across the
region, but still did not meet MDG 6 target 8 of reducing to 50%. LBN, and OMN are the
only two countries that met MDGs 6 target 8 for TB in 2005 . However, TB/HIV comorbidity is growing fast in the region especially in higher HIV epidemic countries such
as DJI, SDN, and SOM.
DOTS population coverage had increased 77 fold between 1995 and 2005, which
is about a 53% increase at the individual country level. This represented a significant
increase in DOTS coverage. In 2005, ARE with 20%, AFG with 81% and IRQ with 87%
coverage had lower DOTS population coverage compared with other countries in the
region.
DOTS new smear-positive case detection rate had increased 45 fold between 1995
and 2005 which is about a 16% increase in each country of the region. In 2005, LBY,
MAR and OMN had over 100% DOTS smear-positive case detection rates whereas WBG
with 2%, ARE 19% and SDN with 35% had lower DOTS smear-positive case detection
rates. Though the EMR had increased DOTS new-smear positive case detection rate, 61%
in 2005, it still did not achieve 1991 NHA target of 70% DOTS new-smear positive case
detection rate.
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DOTS treatment success rate had increased 58% in the EMR which is about a 3%
increase in each country of the region. This indicated progress and the replacement of
Non-DOTS treatment programs. Three countries, however, WBG with 50%, KWT with
63%, and LBY with 64% had lower DOTS treatment success rates in 2005. In spite of
increasing DOTS treatment success rate to 80% in 2005, the EMR as a region did not
meet the 1991 NHA target of 85% DOTS treatment success rate.
In sum, the WHO EMR increased its DOTS population coverage, as demonstrated
by the DOTS new smear-positive case detection rate and DOTS treatment success rate
between 1994 or 1995 and 2004 or 2005, but still did not meet 1991 Forty-fourth World
Health Assembly targets of 70 % DOTS new smear-positive case detect rate and an 85%
DOTS treatment success rate.
It is worth mentioning that LBM and OMN are the only two countries who
achieved both MDGs and DOTS targets between 1990 and 2005.

Pertaining to other demographic, health, socio-economic and political factors in
this study, health workforce, improved sanitation, BCG immunization, adult literacy rate,
political stability, government total health expenditure on health and income had inverse
relationships with TB burden and positive relationships with DOTS population coverage.
However, malnutrition, national poverty level (NPL), HIV and adult smoking rate (ASR)
had positive relationships with TB burden and inverse relationships with DOTS
population coverage.
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Total numbers of health workers and physicians had inverse relationships with TB
burden and positive relationships with DOTS population coverage. The results suggested
increasing the number of health care workers and physicians per 100,000 had the effect
of decreasing TB incidence, prevalence and mortality rates and increasing DOTS
population coverage.
BCG immunization had an inverse relationship with TB burden and a positive
relationship with DOTS within a country. Increasing BCG immunization coverage seems
to have the effect of decreasing TB incidence, prevalence and mortality.
Adult literacy rate had an inverse relationship with TB burden and a positive
relationship with DOTS. In countries where the adult literacy rate was high, TB
incidence, prevalence and mortality rates were low. Also, higher adult literacy rate was
associated with greater DOTS population coverage.
Access to improved sanitation within a country was associated with decreased TB
incidence, prevalence and mortality as well as increased DOTS population coverage.
Developed and stable countries seemed to have somewhat lower rates of TB
incidence, prevalence and mortality. However, developed and stable countries seemed to
have only slightly higher DOTS population coverage. While the relationship between
political stability and the TB burden variables was moderate, the relationship with DOTS
coverage was relatively weak.
GDP and government general health expenditure had weak to moderate
relationships with TB burden and DOTS. In this region, higher GDP and general health
expenditure within a country was associated with lower TB incidence, prevalence and
mortality rates. In additions, higher government general health expenditures were
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associated with greater DOTS coverage. Interestingly, higher GDP seemed to be
associated with lower DOTS population coverage. However, it should be noted that the
correlation coefficient was small and not statistically significant (r s =-.08, p=.716).
National poverty level (NPL), HIV and malnutrition had direct relationships with
TB burden and inverse relationships with DOTS population coverage. When NPL
increased within a country, TB incidence, prevalence and mortality rates increased.
Although these relationships were strong (coefficients >.70) and statistically significant,
it should be noted the sample size was restricted to only seven of the countries in the
region. Again, NPL and malnutrition seemed to have strong negative relationships with
DOTS population coverage. HIV and Adult smoking rates appeared to have weak
positive relationships with TB incidence, prevalence and mortality rates as well as weak
negative relationships with DOTS population coverage. While none of these relationships
were statistically significant, the relationship between HIV and TB mortality remained
noteworthy as it suggested a moderate relationship between HIV and TB mortality (r s =
.46, p=.112).
The other interesting point was an increase in population density decreased TB
incidence, prevalence and mortality rates whereas it increased DOTS population
coverage.
Study Limitations
This was an ecological study--using secondary data-- from WHO World Atlas,
WB, WRI and ACS. The findings of this study describing the current overall situation
regarding TB for the WHO Eastern Mediterranean region may not be generalized to other
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regions in the world or to individual countries in the region. To get more in depth data on
the TB situation, it would be more ideal to have research being performed at the
individual country level which would only be possible given more available resources
and time.
The unit of analysis was at the country level for one specific region, so the sample
size was small (n=22), which has implications (sampling bias, reduced power, less
precision) for any statistical analysis focused specifically on hypothesis testing. However,
the main purpose of this study was to describe the TB situation in this region, not to test
hypotheses with the purpose of generalizing beyond the countries included in the study.
In this case, it is more useful to consider the analyses presented in terms of describing the
characteristics of the TB situation in the EMR.
For some variables, data were not available on an annual basis for all countries
which lead to a considerable amount of missing data. Many variables were not always
available for the entire period. For instance, one variable was available for 20 years,
whereas another was only available for one year. Analysis of data by gender and age was
also not possible due to limitations of reporting methods. The quality of data available
through the sources used in this study was not clear. For example, differences were noted
for the same variable included in different databases as well as differences for some
variables included in the same database in more than one location. And finally, TB/HIV
all ages, MDR-TB and XDR-TB data were not accessible in WHO World Atlas.
Conclusions and Recommendations
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Policy makers and Stop TB stakeholders, in collaboration with scientists and
research institutes, may wish to consider the following recommendations regarding the
improvement of the ongoing TB surveillance and intervention programs in the Eastern
Mediterranean Region of WHO.
We need to allocate more resources to achieve MDG6 (halve TB prevalence and
mortality by 2015 and reverse the incidence of TB) by implementation and extending
Stop TB Strategy in the region, which will also help to achieve targets of 70% of DOTS
detection rate and 85% DOTS treatment success rate in the region.
We should prioritize countries with high TB burden such as AFG and PAK as
well as countries with high TB/ HIV burden such as DJI, SDN and SOM. Strong
commitments and further involvement of economic developed countries such as ARE,
KWT and ASU toward implementation of Stop TB strategy in the region are required.
Enhance coordination and share experiences via conducting annual meetings and
conferences. This will help the members to see their progress, become aware of the
interventions and replicate some feasible interventions to their settings.
Conduct detailed country situation analysis and assessments of TB control
programs, setting targets for each country and tracking the progress. This will help each
country to achieve MDGs via DOTS and Stop TB Strategy.
Perform advocacy, increasing TB information education and communication
(IEC), and social mobilization, especially in countries with a high burden of TB, MDRTB, XDR-TB and TB/HIV co-morbidity.
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Improve TB surveillance system by collecting annual data from all the countries,
and using unified reporting formats to decrease missing values. Also, improve quality of
data and coordination among data producing organizations.
Finally, conduct research and surveillance about some other TB relevant variables
such as TB/HIV all ages, MDR-TB, XDR-TB, age categories and gender. Also,
conducting further research to explore the associations between TB variables and other
sociopolitical variables used in this study.
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Figure 22. TB high-burden Countries (109)

117
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Appendix D
Glossary:
TB terminology
Directly Observed Therapy, Short-course (DOTS) is a proven approach to TB control
that comprises political commitment with increased and sustained financing; case
detection through quality-assured bacteriology; standardized treatment with supervision
and patient support; an effective drug supply and management system; and a monitoring
and evaluation system and impact measurement. Pursuing high-quality DOTS expansion
and enhancement is the first component of the WHO-recommended Stop TB Strategy
(21, 106).
DOTS coverage: ―The percentage of the national population living in areas where health
services have adopted DOTS‖ (21).
Tuberculosis detection rate under DOTS (percentage): ―The proportion of estimated
new smear-positive cases of TB detected (diagnosed and then notified to WHO) by
DOTS programs provides an indication of the effectiveness of national TB programs in
finding and diagnosing people with TB. The case-detection rate is calculated as the
number of new smear positive cases notified divided by the number of new smear
positive cases estimated for that year, expressed as a percentage‖ (21).

120

Tuberculosis treatment success under DOTS (percentage): ―The proportion of new
smear-positive TB cases registered under DOTS in a given year that successfully
completed treatment, whether with or without bacteriological evidence of success
(―cured‖ or ―treatment completed‖ respectively)‖ (21).
Directly Observed Treatment (DOT): ―A trained and supervised person observes the
patient swallowing the medication‖ (21).
DOTS-Plus: ―The adaptation of DOTS to respond to MDR- TB‖ (106).
Targets for TB control established by the 44th World Health Assembly (1991): “To
cure 85% of the sputum smear-positive TB cases detected and to detect 70% of the
estimated new sputum smear-positive TB cases‖ (21).
Drug susceptibility testing (DST): ―Determining in a culture of Mycobacterium
tuberculosis the anti-TB drugs that are effective against that particular sample‖(106).
Green Light Committee (GLC): ―A committee established under the Working Group
on DOTS-Plus for MDR-TB, which reviews applications from potential DOTS-Plus pilot
projects to determine their compliance with guidelines for access to concessionally priced
second-line anti-TB drugs‖(106).
Millennium Development Goals (MDGs): “Time-bound and quantified targets for
addressing various dimensions of development, adopted by world leaders at the United
Nations Millennium Summit in 2000‖ (106).
Practical Approach to Lung Health (PAL): “A comprehensive, symptom-based
approach to the management of patients with respiratory symptoms within the primary
health care system‖(106).
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Public-private mix (PPM) DOTS: “A comprehensive approach to involve all relevant
health care providers (public and private) in providing effective TB services‖(106).
Disability-adjusted life year (DALY): ―A health gap measure that combines the time
lived with disability and the time lost due to premature mortality‖ (106).
Stop TB strategy: ―The new WHO-recommended strategy for TB control elaborated in
2006 that encompasses and goes beyond the DOTS strategy‖ (106).
TB/HIV: ―The interaction between the epidemics of TB and HIV (sometimes refers to
TB patients who also have HIV infection)‖ (106).
TB burden: is defined as TB incidence, prevalence and mortality in this study.
TB Notification: “the process of reporting diagnosed TB cases to WHO; the data
collected by this process. This does not refer to the systems in place in some countries to
inform national authorities of cases of certain "notifiable" diseases. Annual case
notifications (and other data on program performance) are collected by WHO via an
annual data collection form, distributed to national TB control programs through WHO
regional and country offices‖ (107).

Definitions of TB cases

Tuberculosis suspect: ―Any person who presents with symptoms or signs suggestive of
TB, in particular cough of long duration‖ (21).
Case detection: “Activity of identifying infectious cases, mainly among adults attending
an outpatient health facility for any reason with cough for 2 or 3 weeks or more, through
sputum smear examination‖ (21).
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Case of tuberculosis: “A patient in whom tuberculosis has been bacteriologically
confirmed, or has been diagnosed by a clinician‖ (21).
New sputum smear-positive TB case: ―The revised definition of a new sputum smearpositive pulmonary TB case is based on the presence of at least one acid fast bacilli
(AFB+) in at least one sputum sample in countries with a well functioning external
quality assurance (EQA) system‖ (21).
Pulmonary tuberculosis, sputum smear negative (PTB-): “Case of pulmonary
tuberculosis which does not meet the above criteria for smear positive TB. Diagnostic
criteria should include: at least three sputum smear examinations negative for AFB; and
radiographic abnormalities consistent with active pulmonary TB; and no response to a
course of broad-spectrum antibiotics; and a decision by a clinician to treat with a full
course of anti-tuberculosis chemotherapy; or positive culture but negative AFB sputum
examinations‖(21).
Extra-pulmonary tuberculosis: ―Tuberculosis of organs other than the lungs: e.g.
pleura, lymph nodes, abdomen, genito-urinary tract, skin, joints and bones, meninges etc.
Diagnosis should be based on one culture positive specimen, or histological or strong
clinical evidence consistent with active extra-pulmonary tuberculosis, followed by a
decision by a clinician to treat with a full course of anti-tuberculosis chemotherapy. A
patient diagnosed with both pulmonary and extra-pulmonary tuberculosis should be
classified as a case of pulmonary tuberculosis‖(21).
All forms: ―pulmonary (smear-positive and smear-negative) and extra-pulmonary TB‖
(107).
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HIV+ adults: ―Percentage of adults 15–49 who are HIV infected‖ (107).
New Case: “Patient who has never had treatment for TB or has taken anti-tuberculosis
drugs for less than one month‖ (21).
Relapse: ―A patient previously declared cured but with a new episode of
bacteriologically positive (sputum smear or culture)‖ (21)
Treatment outcomes for smear positive pulmonary TB patients
Cured: ―A patient who was initially smear-positive and who was smear-negative in the
last month of treatment and on at least one previous occasion‖ (21).
Completed treatment: “A patient who completed treatment but did not meet the criteria
for cure or failure. This definition applies to pulmonary smear-positive and smearnegative patients and to patients with extra-pulmonary disease‖(21).
Died: “A patient who died from any causes during treatment‖ (21).
Failed: “A patient who was initially smear-positive and who remained smear-positive at
month 5 or later during treatment‖ (21).
Defaulted: “A patient whose treatment was interrupted for 2 consecutive months or
more‖(21).
Transferred Out: “A patient who transferred to another reporting unit and for whom the
treatment outcome is not known‖(21).
Successfully Treated: “A patient who was cured or who completed treatment‖(21) .
Sociopolitical and health terms
Gross Domestic Product (GDP): ―A measure of the size of economies, reported here in
million current US dollars. GDP is the total market value of all final goods and services
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produced in a country in a given year, equal to total consumer, investment, and
government spending‖ (105).
The Political Stability and Absence of Violence Indicator: ― A measure of perceptions
of the likelihood that the government will be destabilized or overthrown by possibly
unconstitutional and/or violent means, including domestic violence and terrorism." Low
scores in this variable indicate that citizens cannot count upon continuity of government
policy or the ability to peacefully select and replace those in power. Values are indexed to
have a mean of zero and a standard deviation of one index unit. Positive scores indicate
better governance and 99% of the values fall between 2.5 and -2.5‖ (105). This variable
was recorded to dichotomous variable of bad governance (0) and good governance (1).
The negative values got bad governance (0) and the positive values got good governance
(1).
Access to improved sanitation: ―measures the total proportion of the population with
access to improved sanitation facilities, expressed as a percentage. Improved sanitation
includes any of the following excreta disposal facilities: connection to a public sewer,
connection to a septic tank, pour-flush latrine, simple pit latrine, ventilated improved pit
latrine, pit latrine with slab, and composting toilet. Improved sanitation facilities are more
likely to be sanitary than unimproved facilities, but are not a direct measure of 'basic'
sanitation--facilities which are "considered the lowest-cost options for safe, hygienic and
convenient facilities that prevent the user and his or her immediate environment from
coming into contact with human excreta. A poor water supply and sanitation system can
lead to a number of diseases, including diarrhea, intestinal worms, and cholera. Examples
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of an unimproved sanitation system include: open pit latrines, public or shared latrines,
service or bucket latrines (where excreta are manually removed), hanging latrines, flush
to elsewhere (street, yard, open sewer, ditch, river, etc.), and no facilities‖ (100).
Government expenditure on health: ―A percent of total expenditure on health is the
percentage of total health expenditures attributable to the national government‖ (100).
National poverty rate: “The percentage of a country's population living below the
country's established national poverty line‖ (100).
Adults and children living with HIV: “An estimate of the total number of adults (aged
15 years and older) and children (aged 0-14) infected with HIV, whether or not they have
developed symptoms of AIDS, alive at the end of the year specified‖ (100).
Adult Literacy Rate: ―Though it varies across countries, the adult literacy rate is usually
defined as the percentage of the population aged 15 years and over who can both read and
write, with comprehension, a short, simple statement regarding their everyday life.
Literacy data can be used to assess gender, age-group, and geographic patterns of
illiteracy within each country, as well as the achievement of national literacy programs
and policies. According to the United Nations Educational, Scientific, and Cultural
Organization (UNESCO), "These estimates reflect the performance of the national
education system, as well as the quality of the human resources within a country in
relation to their potential for growth, contribution to development, and quality of life."
Adult literacy correlates with GNP per capita, life expectancy, fertility rates, infant
mortality, and urbanization‖ (100).
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Population density: “The number of persons per square kilometer of land area. This
dataset is calculated by WRI using population data from the United Nations Population
Division and total land area data from FAOSTAT‖ (100).
Physicians per 100,000 people: “Include graduates of a faculty or school of medicine
who are working in any medical field (including teaching, research and practice) per
100,000 individuals. This is an indicator of the presence of health personnel in a country‖
(100).
Malnutrition: ―Underweight children under five years, moderate and severe, an indicator
of child malnutrition, refers to the proportion of children under 5 whose weight-for-age is
below minus 2 standard deviations (for moderate underweight) or below minus 3
standard deviations (for severe underweight) from the median weight-for-age of an
international reference population recognized by the World Health Organization (WHO).
The values presented here, reported by the United Nations Children Fund (UNICEF),
include both moderately and severely underweight children‖(100).
Income: ―Economies are divided according to 2006 GNI per capita, calculated using the
World Bank Atlas method. The groups are: low income, $905 or less; lower middle
income, $906 - $3,595; upper middle income, $3,596 - $11,115; and high income,
$11,116 or more‖(104). According to WB, developing economic countries are defined as
countries with low and middle income and developed economic countries are defined as
countries with high income and these two recent definitions were used in this study‖
(105).
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